In this report, the global Genetic Testing market is valued at USD XX million in 2019 and is projected to reach USD XX million by the end of 2025, growing at a CAGR of XX% during the period 2019 to 2025.

Persistence Market Research recently published a market study that sheds light on the growth prospects of the global Genetic Testing market during the forecast period (20XX-20XX). In addition, the report also includes a detailed analysis of the impact of the novel COVID-19 pandemic on the future prospects of the Genetic Testing market. The report provides a thorough evaluation of the latest trends, market drivers, opportunities, and challenges within the global Genetic Testing market to assist our clients arrive at beneficial business decisions.

The Genetic Testing market report firstly introduced the basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the Genetic Testing market report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/3175

Resourceful insights enclosed in the report:

The major players profiled in this Genetic Testing market report include:

Some of the major companies dealing in genetic testing market are Abbott Laboratories, BioRad Laboratories, Abbott Molecular Inc., AutoGenomics Inc., Celera Group, PerkinElmer Inc., Quest Diagnostics Inc., ELITech Group, Roche Diagnostics Corp., Applied Biosystems Inc., Roche Molecular Diagnostics Inc., Transgenomic Inc. and others.

Key points covered in the report

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/3175

The market report addresses the following queries related to the Genetic Testing market:

The study objectives of Genetic Testing Market Report are:

To analyze and research the Genetic Testing market status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.

To present the Genetic Testing manufacturers, presenting the sales, revenue, market share, and recent development for key players.

To split the breakdown data by regions, type, companies and applications

To analyze the global and key regions Genetic Testing market potential and advantage, opportunity and challenge, restraints and risks.

To identify significant trends, drivers, influence factors in global and regions

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the Genetic Testing market.

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/3175

Read more:
Genetic Testing Market Is Evenly Poised To Reach A Market Value Of US$ XX Mn/Bn By - The Scarlet

Recommendation and review posted by Bethany Smith

AMSBIO has announced new additions and certifications for its range of clinical grade, chemically defined cryopreservation excipient solutions STEM-CELLBANKER and HSC-BANKER.

STEM-CELLBANKER DMSO Free GMP grade is a new chemically defined freezing solution that does not contain DMSO as an anti-freezing agent. It was developed for customers who prefer not to use DMSO-containing cryopreservation solution due to the intended application of the samples. STEM-CELLBANKER DMSO Free GMP grade is manufactured in compliance with JPN, EU, US, and PIC/S GMP guidelines.

STEM-CELLBANKER is a chemically defined freezing media optimized for stem cells and iPS cells storage, as well as fragile primary cells. Published data supports its ability to cryopreserve organoids and tissues to allow the recovery of viable cells. STEM-CELLBANKER GMP grade is manufactured in compliance with JPN, EU, US, and PIC/S GMP guidelines. Free from animal derived components this popular cryopreservation medium contains only chemically defined USP, EP and JP grade ingredients. Available in both DMSO containing and DMSO-Free formulations, STEM-CELLBANKER is an optimal freezing solution for basic research and is finding widespread use in the clinical application of cell therapy products.

Manufactured to be completely free of serum and animal derived components, HSC-BANKER contains only European or US Pharmacopoeia graded ingredients making it suitable for storage of hematopoietic stem cells developed for cell therapy applications.

Recently the master files of HSC-BANKER were accepted by the Center for Biologics Evaluation and Research (CBER) within the US FDA (Food and Drug Administration). Master files are submissions to the FDA used to provide confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drug products. Beneficially they allow researchers to reference material without disclosing Master file contents to those parties.

HSC-BANKER is supplied ready-to-use and requires no special devices, such as a controlled rate freezer, in order to achieve consistently high viabilities following resuscitation from cryopreservation, even over extended long-term storage. HSC-BANKER significantly increases cell viability while maintaining cell pluripotency, normal karyotype and proliferation ability after freeze-thaw. Evaluated for endotoxins, pH, osmolarity and mycoplasma contaminants to ensure GMP equivalent quality. HSC-BANKER is part of the CELLBANKER range of cryopreservation media for cells, organoids and tissues.

Link:
Optimized Freezing Solutions for Clinical Application of Cell Therapy Products - technologynetworks.com

Recommendation and review posted by Bethany Smith

The global Stem Cell-Derived Cells market study presents an all in all compilation of the historical, current and future outlook of the market as well as the factors responsible for such a growth. With SWOT analysis, the business study highlights the strengths, weaknesses, opportunities and threats of each Stem Cell-Derived Cells market player in a comprehensive way. Further, the Stem Cell-Derived Cells market report emphasizes the adoption pattern of the Stem Cell-Derived Cells across various industries.

The Stem Cell-Derived Cells market report examines the operating pattern of each player new product launches, partnerships, and acquisitions has been examined in detail.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/28780

key players in stem cell-derived cells market are focused on generating high-end quality cardiomyocytes as well as hepatocytes that enables end use facilities to easily obtain ready-made iPSC-derived cells. As the stem cell-derived cells market registers a robust growth due to rapid adoption in stem cellderived cells therapy products, there is a relative need for regulatory guidelines that need to be maintained to assist designing of scientifically comprehensive preclinical studies. The stem cell-derived cells obtained from human induced pluripotent stem cells (iPS) are initially dissociated into a single-cell suspension and later frozen in vials. The commercially available stem cell-derived cell kits contain a vial of stem cell-derived cells, a bottle of thawing base and culture base.

The increasing approval for new stem cell-derived cells by the FDA across the globe is projected to propel stem cell-derived cells market revenue growth over the forecast years. With low entry barriers, a rise in number of companies has been registered that specializes in offering high end quality human tissue for research purpose to obtain human induced pluripotent stem cells (iPS) derived cells. The increase in product commercialization activities for stem cell-derived cells by leading manufacturers such as Takara Bio Inc. With the increasing rise in development of stem cell based therapies, the number of stem cell-derived cells under development or due for FDA approval is anticipated to increase, thereby estimating to be the most prominent factor driving the growth of stem cell-derived cells market. However, high costs associated with the development of stem cell-derived cells using complete culture systems is restraining the revenue growth in stem cell-derived cells market.

The global Stem cell-derived cells market is segmented on basis of product type, material type, application type, end user and geographic region:

Segmentation by Product Type

Segmentation by End User

The stem cell-derived cells market is categorized based on product type and end user. Based on product type, the stem cell-derived cells are classified into two major types stem cell-derived cell kits and accessories. Among these stem cell-derived cell kits, stem cell-derived hepatocytes kits are the most preferred stem cell-derived cells product type. On the basis of product type, stem cell-derived cardiomyocytes kits segment is projected to expand its growth at a significant CAGR over the forecast years on the account of more demand from the end use segments. However, the stem cell-derived definitive endoderm cell kits segment is projected to remain the second most lucrative revenue share segment in stem cell-derived cells market. Biotechnology and pharmaceutical companies followed by research and academic institutions is expected to register substantial revenue growth rate during the forecast period.

North America and Europe cumulatively are projected to remain most lucrative regions and register significant market revenue share in global stem cell-derived cells market due to the increased patient pool in the regions with increasing adoption for stem cell based therapies. The launch of new stem cell-derived cells kits and accessories on FDA approval for the U.S. market allows North America to capture significant revenue share in stem cell-derived cells market. Asian countries due to strong funding in research and development are entirely focused on production of stem cell-derived cells thereby aiding South Asian and East Asian countries to grow at a robust CAGR over the forecast period.

Some of the major key manufacturers involved in global stem cell-derived cells market are Takara Bio Inc., Viacyte, Inc. and others.

The report covers exhaustive analysis on:

Regional analysis includes

Report Highlights:

Buy the report at a discounted rate!!! Exclusive offer!!!

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/28780

The Stem Cell-Derived Cells market report offers a plethora of insights which include:

The Stem Cell-Derived Cells market report answers important questions which include:

The Stem Cell-Derived Cells market report considers the following years to predict the market growth:

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/28780

Why Choose Stem Cell-Derived Cells Market Report?

Stem Cell-Derived Cells Market Reportfollows a multi- disciplinary approach to extract information about various industries. Our analysts perform thorough primary and secondary research to gather data associated with the market. With modern industrial and digitalization tools, we provide avant-garde business ideas to our clients. We address clients living in across parts of the world with our 24/7 service availability.

Continued here:
Stem Cell-Derived Cells Market Forecast to 2025: Global Industry Analysis by Top Players, Types, Key Regions and Applications - The Scarlet

Recommendation and review posted by Bethany Smith

The parents of a girl battling a deadly blood disorder are begging people to join the stem cell donor register to save her life after her only match in the world pulled out at the last minute.

Evie Hodgson, eight, who suffers from aplastic anaemia, was due to have a bone marrow transplant this month but her donor backed out at the last possible moment.

Her mum, Tina, says the chances of finding another donor are so slim that doctors are now planning a different course of treatment. But, in future, a stem call transplant is Evies best hope of being cured.

The schoolgirl, from Whitby, North Yorks, was first taken to hospital with a rash and was diagnosed with aplastic anaemia in May.

After a global donor search was launched, a 10/10 match was found and the anonymous donor agreed to the procedure. In preparation, Evie had to have dental work and one of her ovaries was removed. But on August 14 the donor pulled out.

Tina, 37, who works at RAF Flyingdales, in Pickering, North Yorks, said: We were devastated, it was a huge blow. We have no idea why the donor changed their mind. Evie has already been through so much. She thought she had a donor and now she doesnt.

The donor pulling out is quite hard-hitting, but we want to raise awareness of the stem cell register. Its so easy to be a donor. Its just like giving blood, but you could save a childs life. Its so easy to join but only 1% of the UK population is registered.

Evie said: I need this transplant to save my life. Please sign the register to help.

Tina added: The condition Evie has is life-threatening. She wont survive without a transplant. We are desperately appealing for people to sign the stem cell register.

Evie was diagnosed with the condition after she developed a pin-prick rash on her back, which didnt fade. Tests revealed she had low blood platelet levels and she was told she needed a bone marrow transplant.

Aplastic anaemia is a rare life-threatening condition where the bone marrow fails to produce enough blood cells. Around 100-150 people are diagnosed in the UK each year.

Treatment can include immunosuppressants, chemotherapy, blood transfusions, or blood and bone marrow transplants.

Neither Tina, dad Andy, 49, or brother William, five, were a match and so an international search was launched.

Tina said: Our world crumbled when Evie was diagnosed. Evie knew shed need chemotherapy. She donated her hair to The Little Princess Trust, after making friends with poorly children who have lost all their hair.

Evie will be treated with immunosuppressants while the search for a donor continues.

See the original post:
Parents plea for stem cell help to save life of daughter with rare blood disorder - Mirror Online

Recommendation and review posted by Bethany Smith

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vor Biopharma, an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, and Metagenomi, a gene editing company discovering breakthrough systems for curing genetic disease, today announced that Vor will evaluate the potential use of Metagenomis gene editing technology to develop engineered hematopoietic stem cell-based therapies for the treatment of blood cancers, such as acute myeloid leukemia.

Cancer patients deserve therapies with strong effects on cancer cells and minimal effects on all other cells, said Tirtha Chakraborty, Ph.D., Vors VP and Head of Research. Our new partnership with Metagenomi will help us achieve this goal by engineering hematopoietic stem cells using precise yet flexible gene editing thereby ensuring that targeted therapies can live up to their name."

The collaboration is non-exclusive and applies to pre-clinical research only. Further terms of the agreement are not being disclosed.

This partnership unites two transformative technologies our proprietary gene editing enzymes, and Vors platform for engineering hematopoietic stem cells such that they are inherently treatment-resistant, said Brian C. Thomas, Metagenomis CEO and co-founder. We are excited to be working together to bring both of these cutting-edge approaches into the clinic.

About Vor Biopharma

Vor Biopharma aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell (eHSC) therapies. By removing biologically redundant proteins from eHSCs, these cells become inherently invulnerable to complementary targeted therapies while tumor cells are left susceptible, thereby unleashing the potential of targeted therapies to benefit cancer patients in need.

Vors platform could be used to potentially change the treatment paradigm of both hematopoietic stem cell transplants and targeted therapies, such as antibody drug conjugates, bispecific antibodies and CAR-T cell treatments.

Vor is based in Cambridge, Mass. and has a broad intellectual property base, including in-licenses from Columbia University, where foundational work was conducted by inventor and Vor Scientific Board Chair Siddhartha Mukherjee, MD, DPhil.

About VOR33

Vors lead product candidate, VOR33, consists of engineered hematopoietic stem cells (eHSCs) that lack the protein CD33. Once these cells are transplanted into a cancer patient, we believe that CD33 will become a far more cancer-specific target, potentially avoiding toxicity to the normal blood and bone marrow associated with CD33-targeted therapies. Vor aims to improve the therapeutic window and effectiveness of CD33-targeted therapies, thereby potentially broadening the clinical benefit to patients suffering from acute myeloid leukemia.

About Metagenomi

Metagenomi is harnessing the vast information found in life on Earth to develop cures for genetic disease. Using proprietary data collected from around the world, Metagenomi has developed novel gene editing tools that enable next-generation gene and cell therapies.

Metagenomi is based out of Emeryville, California, and was founded by pioneers in the field of metagenomics, Jill Banfield and Brian C. Thomas. Metagenomi generates massive quantities of data from natural environments, producing complete genomes from organisms that are otherwise unknown. Metagenomi then unlocks the information captured in these genomes to develop game-changing in vivo and ex vivo therapeutics.

Visit link:
Vor Biopharma and Metagenomi to Collaborate on Engineered Hematopoietic Stem-Cell Therapies - Business Wire

Recommendation and review posted by Bethany Smith

A California woman may be the first person to be cured of HIV without a bone marrow transplant, according to a recent report in Nature. More than 60 other so-called elite controllers, who have unusually potent immune responses to HIV, were found to have their virus sequestered in parts of their genome where it is unable to replicate.

The unusual case involves Loreen Willenberg, who acquired HIV in 1992. Her immune system has maintained control of the virus for decades without the use of antiretroviral treatment, and researchers have been unable to find any intact virus in more than 1.5 billion of her cells. Elite controllers are thought to make up less than half a percent of all people living with HIV.

I believe Loreen might indeed meet anyones definition of a cure, study coauthor Steven Deeks, MD, of the University of California at San Francisco, told POZ. Despite heroic efforts, we just could not find any virus that is able to replicate. Her immune system seems completely normal. Even her HIV antibodies levels are low, which is unprecedented in an untreated person.

Although antiretroviral therapy can keep HIV replication suppressed, the virus inserts its genetic material into the chromosomes of human cells, making it very difficult to eradicate. HIV can lie dormant in a reservoir of resting immune cells indefinitely, but when antiretrovirals are stopped and the cells become activated, they can start churning out new virus.

Previously, only two people were known to have been cured of HIV: Timothy Ray Brown, formerly know as the Berlin Patient, and a man in London. Both received bone marrow stem cell transplants from a donor with a rare genetic mutation that makes cells resistant to HIV entry. But this procedure is far too dangerous for people who dont need it to treat advanced cancer.

The new research suggests that Willenberg and some five dozen other people with long-term untreated HIV have their virus hidden away in their cells genomes in such a way that the viral genetic blueprint (known as a provirus) cant be used to produce new viral particles that can go on to infect other cells.

Xu Yu, MD, of the Ragon Institute of Massachusetts General Hospital, MIT and Harvard analyzed integrated HIV in millions of cells from 64 elite controllers and 41 typical HIV-positive people on antiretroviral therapy recruited at Mass General and San Francisco General Hospital.

In both groups, about 20% were women, the average age was approximately 56 and they had been living with HIV for an average of 17 years and had undetectable virus according to standard tests for nine years. Overall, the elite controllers had a higher average CD4 count (about 900 versus 70, respectively).

The researchers used next-generation gene sequencing to characterize the participants viral blueprints, including where they were inserted into human chromosomes. They found that the elite controllers had fewer integrated proviruses, but a larger proportion of them were intact, or potentially capable of replicating. The virus in these individuals was highly consistent, without the wide variety of mutations seen in most people with HIV.

Whats more, their proviruses were integrated at distinct sites in the human genome, farther away from elements that enable viral replication. Specifically, the integrated DNA was not located near sites that switch on transcription or close to accessible chromatin, which contains histone proteins that package long DNA strands into a more compact form. The DNA must then be unwound from these proteins before it can be used to produce new virus.

These data suggest that a distinct configuration of the proviral reservoir represents a structural correlate of natural viral control and that the quality, rather than the quantity, of viral reservoirs can be an important distinguishing feature for a functional cure of HIV-1 infection, Yu and colleagues wrote.

In a commentary accompanying the report, Nicolas Chomont, PhD, of the University of Montreal, characterized the proviruses in these elite controllers as being in a state of deep sleep compared with latent virus in typical people with HIV. This has only now become apparent because researchers have more sophisticated tools to pinpoint the location of proviruses within the genome.

It is unclear why this block and lock phenomenon happens in only a small proportion of people with HIV. Its possible that the virus ends up sequestered in these locations by chance. But the researchers think its more likely that the integrated proviruses at these sites are evolutionarily selected over time as the ones in locations more conducive to viral replication are eliminated by the immune system.

In Willenbergs case, the research team analyzed more than 1.5billion of her peripheral blood immune cells, including samples from gut tissue, where the virus often hides. Theycould not find any intact proviruses that could be used to produce new HIV. Given her lack of intact proviruses, the researcherswere unable to determine whether she ever fit the pattern of having latent HIV locked away in inaccessible locations.

Another 11 people, dubbed exceptional controllers, only had detectable provirusesatremote sites in the genome where it could not replicate.Since this study, the researchers have discovered a couple more elite controllers who may qualify as additional cures, according to The New York Times.

This raises the possibility that a sterilizing cure of HIVmeaning complete eradicationmay be feasible in rare instances, the study authors suggested. A similar but less complete process may be at play in the subset of about 10% of people with HIV who maintain viral suppression after stopping antiretroviral therapy but who still have detectable proviruses (known as post-treatment controllers).

This research was first presented at the International AIDS Society Conference on HIV Science last summer, where Willenberg was referred to as the San Francisco Patient. Willenberg later went public with her status, and she and Yu discussed the study findings during a webinar with HIV cure advocates last November.

I broke out in tears when I saw Dr. Yus final slide, said Willenberg, who over the years has participated in more than a dozen studies. I can only hope and pray that with continued dedication we can figure out how I have dumped the virus into the DNA junkyard.

The question now is whether its possible to develop treatments that could enable the millions of typical people with progressive HIV to become elite controllers like Willenberg. Chomont suggested that immune-based therapiesincluding CAR-T cellsmight be able to shrink the viral reservoir until it consists only of deeply latent proviruses that are unable to replicate.

The key question is, How did her immune system achieve this remarkable state? Deeks said. We do not know. We need to find more people who are exceptional controllers like Loreen and get to work on figuring out the mechanism.

In this video fromamfAR, the Foundation for AIDS Research,Loreen Willenbergtalks about living as an elite controller of HIV.

Click here to read the Nature article.Click here for more news about HIV cure research.

Read the original:
First Woman May Be Cured of HIV Without a Bone Marrow Transplant - POZ

Recommendation and review posted by Bethany Smith

SAN DIEGO Cystinosis is a disease that slowly and aggressively attacks your organs, tissues, muscles, bones, eyes, even your brain.

It's a genetic disorder with no cure.

And right now, the only option for treatment is an army of pills to slow it down but missing even one dose can be devastating.

Now one man is "patient one", the first to try a new treatment that may save thousands of lives.

21-year old Jordan Janz is living with the rare, unrelenting disorder.

"I was diagnosed at eight months old and basically have been living with it my whole life."

In Jordan, cystine, an amino acid, gets trapped in his cells.

When cystine levels rise, crystals build up all over the body leaving a trail of damage... even causing him to vomit up to 13 times a day.

"It's not how strong you are physically," he said.

"I think it's how strong you are mentally when you come into this."

Traditional cystinosis treatments aim to slow the build up of cystine inside cells.

In order to do that Jordan takes 56 pills each day, but now he hopes to change that, Jordan is the first patient to test a unique gene therapy.

UC San Diego professor Stephanie Cherquie's took stem cells from Jordan's bone marrow, re-engineered the cells, introduced genes that will produce cystinosin, then reinfused Jordan with his own cystinosin-producing cells.

"So, then these cells become a source of healthy stem cells for the rest of the life of the patient," said Stephanie.

Jordan had to take chemo twice a day, but he hasn't let that scare him away.

"I'm doing this obviously for other cystinosis families, right?," said Jordan.

Hoping that many others after him will now get the chance at a better, longer life.

For those born with cystinosis who make it into adulthood, the average lifespan is around 28 years old.

We're told Jordan Janz is making a good recovery. though it is still too soon to tell his long-term prognosis.

If this story has impacted your life or prompted you or someone you know to seek or change treatments, please let us know by contacting Jim Mertens atjim.mertens@wqad.comor Marjorie Bekaert Thomas atmthomas@ivanhoe.com.

Continued here:
YOUR HEALTH: When the body turns to crystals - WQAD.com

Recommendation and review posted by Bethany Smith

Share this Article

You are free to share this article under the Attribution 4.0 International license.

Researchers have found a way, in mice and human tissue, to regenerate the cartilage that eases movement between bones.

Loss of this slippery and shock-absorbing tissue layer, called articular cartilage, is responsible for many cases of joint pain and arthritis, which afflicts more than 55 million Americans.

The researchers can envision a time when people are able to avoid getting arthritis in the first place by rejuvenating their cartilage before it is badly degraded.

Nearly 1 in 4 adult Americans suffer from arthritis, and far more are burdened by joint pain and inflammation generally.

The researchers figured out how to regrow articular cartilage by first causing slight injury to the joint tissue, then using chemical signals to steer the growth of skeletal stem cells as the injuries heal.

Cartilage has practically zero regenerative potential in adulthood, so once its injured or gone, what we can do for patients has been very limited, says co-senior author Charles K.F. Chan, assistant professor of surgery at Stanford Universitys School of Medicine.

Its extremely gratifying to find a way to help the body regrow this important tissue, Chan says.

The work builds on previous research that resulted in isolation of the skeletal stem cell, a self-renewing cell that is also responsible for the production of bone, cartilage and a special type of cell that helps blood cells develop in bone marrow.

Articular cartilage is a complex and specialized tissue that provides a slick and bouncy cushion between bones at the joints. When this cartilage is damaged by trauma, disease, or simply thins with age, bones can rub directly against each other, causing pain and inflammation, which can eventually result in arthritis.

Damaged cartilage can be treated through a technique called microfracture, in which tiny holes are drilled in the surface of a joint. The microfracture technique prompts the body to create new tissue in the joint, but the new tissue is not much like cartilage.

I realized the only way to understand the process was to look at what stem cells are doing after microfracture.

Microfracture results in what is called fibrocartilage, which is really more like scar tissue than natural cartilage, says Chan. It covers the bone and is better than nothing, but it doesnt have the bounce and elasticity of natural cartilage, and it tends to degrade relatively quickly.

The most recent research arose, in part, through the work of surgeon and lead author Matthew Murphy, a visiting researcher at Stanford who is now at the University of Manchester.

I never felt anyone really understood how microfracture really worked, Murphy says. I realized the only way to understand the process was to look at what stem cells are doing after microfracture.

For a long time, Chan says, people assumed that adult cartilage did not regenerate after injury because the tissue did not have many skeletal stem cells that could be activated. Working in a mouse model, the team documented that microfracture did activate skeletal stem cells. Left to their own devices, however, those activated skeletal stem cells regenerated fibrocartilage in the joint.

But what if the healing process after microfracture could be steered toward development of cartilage and away from fibrocartilage?

The researchers knew that as bone develops, cells must first go through a cartilage stage before turning into bone. They had the idea that they might encourage the skeletal stem cells in the joint to start along a path toward becoming bone, but stop the process at the cartilage stage.

The researchers used a powerful molecule called bone morphogenetic protein 2 (BMP2) to initiate bone formation after microfracture, but then stopped the process midway with a molecule that blocked another signaling molecule important in bone formation, called vascular endothelial growth factor (VEGF).

What we ended up with was cartilage that is made of the same sort of cells as natural cartilage with comparable mechanical properties, unlike the fibrocartilage that we usually get, Chan says. It also restored mobility to osteoarthritic mice and significantly reduced their pain.

As a proof of principle that this might also work in humans, the researchers transferred human tissue into mice that were bred to not reject the tissue, and were able to show that human skeletal stem cells could be steered toward bone development but stopped at the cartilage stage.

The next stage of research is to conduct similar experiments in larger animals before starting human clinical trials. Murphy points out that because of the difficulty in working with very small mouse joints, there might be some improvements to the system they could make as they move into relatively larger joints.

The first human clinical trials might be for people who have arthritis in their fingers and toes. We might start with small joints, and if that works we would move up to larger joints like knees, Murphy says.

Right now, one of the most common surgeries for arthritis in the fingers is to have the bone at the base of the thumb taken out. In such cases we might try this to save the joint, and if it doesnt work we just take out the bone as we would have anyway. Theres a big potential for improvement, and the downside is that we would be back to where we were before.

One advantage of their discovery is that the main components of a potential therapy are approved as safe and effective by the FDA, says co-senior author Michael Longaker, professor of surgery.

BMP2 has already been approved for helping bone heal, and VEGF inhibitors are already used as anti-cancer therapies, he says. This would help speed the approval of any therapy we develop.

Joint replacement surgery has revolutionized how doctors treat arthritis and is very common: By age 80, 1 in 10 people will have a hip replacement and 1 in 20 will have a knee replaced. But such joint replacement is extremely invasive, has a limited lifespan and is performed only after arthritis hits and patients endure lasting pain.

The researchers say they can envision a time when people are able to avoid getting arthritis in the first place by rejuvenating their cartilage in their joints before it is badly degraded.

One idea is to follow a Jiffy Lube model of cartilage replenishment, Longaker says. You dont wait for damage to accumulateyou go in periodically and use this technique to boost your articular cartilage before you have a problem.

The work appears in the journal Nature Medicine.

Support for the research came from the National Institutes of Health, the California Institute for Regenerative Medicine, the Oak Foundation, the Pitch Johnson Fund, the Gunn/Olivier Research Fund, the Stinehart/Reed Foundation, The Siebel Foundation, the Howard Hughes Medical Institute, the German Research Foundation, the PSRF National Endowment, National Center for Research Resources, the Prostate Cancer Research Foundation, the American Federation of Aging Research, and the Arthritis National Research Foundation.

Source: Stanford University

Read more:
Method regrows cartilage to cushion bones - Futurity: Research News

Recommendation and review posted by Bethany Smith

Mesoblast's (MESO) stock has grown over 300% since we last made out an investment case in March 2019, and an IOM runthrough six months prior, based on phase 2 trial data in acute graft versus host disease (aGVHD). Presently, the United States Food and Drug Administration (FDA) has accepted the companys Biologics License Application (BLA) for priority review of its phase 3 product candidate RYONCIL (remestemcel-L) for steroid-refractory aGVHD in children. The Prescription Drug User Fee Act (PDUFA) action date is set at 9/30/2020, and if approved, Mesoblast is geared up to make RYONCIL available immediately in the U.S. mid-August, an FDA advisory committee has already backed approval with a 9-1 vote.

Speaking at the 2020 Full-Year Financial Results and Corporate Highlights Webcast on 8/27/2020, CEO Dr. Silviu Itescu said the lead product candidate RYONCIL has a targeted market. If approved, the launch for this product is planned in 2020, and we have industrial scale manufacturing in place to meet the commercial demand as we expect to move forward.

The company has well-established plans for life cycle expansion of remestemcel in pediatric and adult inflammatory diseases, including a Phase 3 trial ongoing in patients with acute respiratory distress syndrome from COVID-19, and two additional product candidates in Phase 3 trials for heart failure and back pain with near-term U.S. readouts.

Cash-wise, Mesoblast is presently in a comfortable position. It has sufficient runway for transitioning to a commercial organization with its own product sales.

Mesoblast uses a proprietary technology platform developing mesenchymal lineage cells that are found in every vascularized tissue around blood vessels. They express a number of receptors for various inflammatory cytokines, including TNF-alpha receptor, IL-1 receptor, IL-6 receptor, interferon gamma receptor. They are activated when introduced in the middle of a cytokine storm, and release anti-inflammatory mediators to regulate and control multiple arms of the immune system thereby switching off the severe inflammatory response that is responsible for the damage to tissues forming the basis of the diseases that the company is targeting.

Mesenchymal lineage cells are collected from the bone marrow of healthy adult donors and proprietary processes are utilized to expand them to a uniform, well characterized, and highly reproducible cell population. This enables manufacturing at industrial scale for commercial purposes. Another key feature of Mesoblasts cells is they can be administered to patients without the need for donorrecipient matching or recipient immune suppression. (from company website)

Remestemcel is the companys most advanced product candidate being developed for pediatric and adult systemic inflammatory conditions. The most advanced indication is for pediatric steroid-refractory aGVHD. It is also being developed for adult steroid-refractory aGVHD and chronic GVHD. A phase 3 trial is ongoing for acute respiratory distress syndrome (ARDS) caused by COVID-19. Its also being developed for biologic refractory Crohns disease.

Image source: company website

The companys products for localized inflammatory diseases are based on the rexlemestrocel platform. These include REVASCOR for advanced chronic heart failure and MPC-06-ID for chronic low back pain due to degenerative disc disease, which are in phase 3 with readouts expected in the upcoming quarter.

Trial data from the three phase 3 trials of RYONCIL for pediatric steroid-refractory aGVHD is summarized below. (Source: news release dated 5/25/2020.)

Three trials evaluated the same treatment regimen of RYONCIL, with patients receiving twice weekly intravenous infusions of 2 million cells per kg body weight over a four-week period.

Study 275: An Expanded Access Program in 241 children across 50 centers in eight countries where RYONCIL was used as salvage therapy for steroid-refractory acute GVHD in patients who failed to respond to steroid therapy as well as multiple other agents.

Study GVHD001/002: A Phase 3 single-arm trial in 55 children across 20 centers in the United States where RYONCIL was used as the first line of treatment for children who failed to respond to steroids for acute GVHD.

Study 280: A Phase 3 randomized placebo-controlled trial in 260 patients, including 28 children, across 72 centers in seven countries where RYONCIL or placebo were added to second line therapy in patients with steroid-refractory acute GVHD who failed to respond to steroid treatment.

Study 275: Day 28 Overall Response (OR), the primary endpoint, was achieved in 65% of subjects. Survival through 100 days was significantly greater in patients who achieved a day 28 OR (82%) compared with patients that did not achieve day 28 OR (39%), with 67% overall day 100 survival.

Study GVHD001/002:

Consistent with the findings in Study 275, Day 28 OR was achieved in 70% of children. This was statistically significant compared to the pre-specified control value of 45% (70.4% versus 45%, P =0.0003). As in study 275, clinical response at day 28 was highly predictive of improved survival through day 100 (87% compared to 47% in patients that did not achieve day 28 OR P = 0.0001). Similar predictive value of day 28 was also seen in survival through day 180 (79% vs. 43.8%, P= 0.003). Overall survival was 74.1% at day 100 and 68.5% at day 180.

These results were significantly higher than those from matched control pediatric subjects from the contemporaneous database of the Mount Sinai Acute GVHD International Consortium (MAGIC), accessed to provide an unbiased and independent estimate of response rates and outcomes in matched pediatric control patients treated with institutional standard of care. In the MAGIC controls, Day 28 OR was 43% and Day 100 survival was 57%.

Study 280:

Among high-risk children and adults who had the most severe disease stages, day 28 OR was significantly greater in the RYONCIL treated group (58% versus 37%; P = 0.03) compared to placebo. Among the standard risk patients there was no significant benefit of RYONCIL treatment. Within the pediatric patients in this study (n=28) day 28 OR was significantly greater in the RYONCIL group compared with the placebo group (64% vs. 36%, respectively, P=0.05).

These Phase 3 results provide prospective, randomized controlled data which are supportive for the use of RYONCIL in children and high-risk adults with steroid-refractory acute GVHD.

RYONCIL was well-tolerated in all studies with no identified safety concerns.

52-week range: $3.12-$21.28

Last close: $18.58 (8/27/2020)

Market cap.: $2.17B

Cash balance: $129.3M (Jun-2020)

Cash burn: $82.3M (FY-2020)

Cash runway: 1.57 excl. revenue; 3.01 incl. revenue

Revenue: ~$32.2M (Jun-2020); estimated: ~$119M (Jun-2021), ~$314M (Jun-2022)

The company raised $90 million in May 2020 from existing and new institutional investors. The proceeds from the offering will be used for commercial launch of RYONCIL for acute GVHD, will also support a scale-up of manufacturing for... maturing pipeline, including GVHD label extensions and for COVID-19 ARDS and also support the clinical programs underlying those. Additionally, up to $67.5 million may be available through existing strategic partnerships and ongoing financing facilities over the next 12 months.

The company has an extensive portfolio of over 1,100 patents and patent applications that cover compositions of matter, manufacturing and therapeutic applications of mesenchymal lineage cells with protection extending through 2040 in all major markets.

The company has licensing and royalty agreements with Japan based JCR Pharmaceuticals (OTCPK:JCRRF) for their product, TEMCELL, with Grunenthal for MPC-06-ID for the Europe and Latin America regions, and with Tasly for REVASCOR for the China region. The company garnered revenue of ~$32 million in fiscal 2020 from these arrangements.

Acute GVHD occurs in approximately 50% of patients who receive an allogeneic bone marrow transplant (BMT). Over 30,000 patients worldwide undergo an allogeneic BMT annually, primarily during treatment for blood cancers, and these numbers are increasing. In patients with the most severe form of acute GVHD (Grade C/D or III/IV), mortality is as high as 90% despite optimal institutional standard of care.

There are currently no FDA-approved treatments in the United States for children under 12 with steroid-refractory acute GVHD.

Mesenchymal Stem Cells (MSC) based therapy looks like the most promising of the various third-line treatment options in consideration, and is at the most advanced stage towards approval.

Since I first recommended MESO to our subscribers, the stock has multiplied many times over. Now, right before PDUFA, there does not seem to be much opportunity, especially since the positive adcom has probably priced in the PDUFA as well. Sure, there is always some spike before the major date, but I would rather buy after the approval, when stocks almost always go down. There may even be a dilution given the not-so-strong cash position of the company. But after that, the company predicts a steady revenue stream and so on; buyout offers are also not unlikely. Given that, this would be the right time to purchase the stock in my opinion.

Thanks for reading. At the Total Pharma Tracker, we do more than follow biotech news. Using our IOMachine, our team of analysts work to be ahead of the curve.

That means that when the catalyst comes that will make or break a stock, weve positioned ourselves for success. And we share that positioning and all the analysis behind it with our members.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Go here to read the rest:
Mesoblast Before The PDUFA - Seeking Alpha

Recommendation and review posted by Bethany Smith

During a virtual Case Base Peer Perspectives event, Eleni Efstathiou, MD, PhD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX discussed treatment options for a 57-year-old African American man with nonmetastaic castration resistant prostate cancer (CRPC)

CASE:

October 2016

November 2016

February 2017

October 2019 - Restaging

Targeted OncologyTM: What are your impressions of this case?

Efstathiou: It looks [as though] after he nadired, he quickly recurred with a detectable PSA and a doubling time of 8.6 months. This is a case thats pointing toward the nonmetastatic castration-resistant prostate cancer [CRPC] status. And in the case, we dont have it, but testosterone would be checked, and it is within the castrate levels.

According to the case, this was followed with conventional imaging. This gentleman is now 60 years old in October 2019.

According to the case, the patient refused [radiotherapy]. Having said that, if you look at the data from the phase 3 trials that were done, you would see that 24% of patients who were included, at least in 1, had not been offered any treatment at the beginning, at their diagnosis, even of their primary [tumor]. So its quite impressive that still, to this day, a lot of patients do not get radiation even on the primary [tumor] when it is needed, and it calls for more education. We dont know if these cases were from the European side, the Asia side, or the United States side. Its not exactly granular, but it was disappointing for me to see.

Would you get advanced testing done for this patient?

Ive been sending patients who can [go for PSMA PET] to University of California, Los Angeles, recently, because I believe that Axumin and PSMA, looking at the data, are equally sensitive. However, it appears that PSMA is more specific. Ive had a lot of false positives on PETs. Im not pointing fingers, but its from different places that I got them, so Im not relying on the results. But, for this case, if the Axumin is still lining up in the prostate, then you have a clear move forward. But, to this day, for nonmetastatic CRPC or for PSA-recurring CRPC only, we do not have an indication to do the PET scan. That is in line with these studies being done with conventional imaging, and that can be a concern with approvals.

Now, this man was given conventional imaging, and this is more the standard across the board.

Do you actively pursue germline testing in high-risk disease or metastatic disease?

I was recently on an ad board, and I was speaking to people from Duke University, Mayo Clinic, and the like. Nobody has any systemic approach yet, and its not even routine in most cases. Its up to the physicians, and it can be more taxing that way, I find, because its 1 more thing added and sometimes can be missed. So I hope that in the future it will become as straightforward as doing the PSA, doing the testosterone, and [other processes such as that].

What are your thoughts on the results of this poll? What would you have voted for?

Most seem to have gone for any of the novel hormonal agents. Somebody put down chemotherapy. Somebody else also voted for nilutamide, flutamide, or bicalutamide.

I would go for other.

Seventy-seven percent voted for enzalutamide [Xtandi], apalutamide [Erleada], darolutamide [Nubeqa], or abiraterone [Zytiga].

How would you compare these agents?

Ive been starting to use [darolutamide] recently. Its approval was more recent.

I dont see a big difference between enzalutamide and apalutamide, not only in the fatigue, per se, but also the central nervous system [CNS] effect, which has to do with some extra depression, some extra insomnia, some extra effects that are not trivial. The difference is small [between these 2]. But the claim from the preclinical data was that apalutamide would have less of a CNS impact. Of course, when you test it in humans is when you see the real deal, and more so in the real-world experience.

With enzalutamide, my experience had always been that at least I can draw a line that I can say if a patient is over 70 years old, he may not perform that well. But, more recently, Ive even seen young men not being able to tolerate it.

And, in the case of this patient, I would say that we should all agree that both enzalutamide and apalutamide would be totally contraindicated because of the seizure disorder. So darolutamide is the only path forward.

What about abiraterone?

These [other] 3 drugs have an indication for nonmetastatic CRPC. Would you expect the insurance to go for abiraterone? I would find it hard [to believe the insurance would accept it,] because its not within the indication.

What are the takeaways from this poll?

Essentially, the bottom line is, you dont see any difference in the efficacy between the 3 agents, but you see an advantage in the safety profile.

Im starting to use darolutamide more, and I was reluctant at first. But now that most data are out, I would say I would agree; theres nothing holding me back in that aspect.

CASE (continued)

After shared decision-making, darolutamide was initiated.

What are your thoughts on the choice of darolutamide?

[The PSA doubling time] was a major concern in the beginning and now, as of this ASCO [American Society of Clinical Oncology Annual Meeting], we have overall survival [OS] data that exceed a year in the CRPC space, which has not been shown before.

I dont know how patients tolerate it yet. I gradually started to give it to the first patient, the second, but Ive got about 10 patients who are on it now, so Im getting there. Its a big deal, because I always say that if we havent had the hands-on experience in research or a clinical trial, it hits the market and then youre [deciding], I dont know this drug, Im going to stay with my comfort level. I can use enzalutamide and abiraterone blindfolded, but it looks [as though] darolutamide is going to be pretty easy. I want to see their data.

My only thing is I want to see more data coming from them with regards to bone density, and I think theyre getting ready to give those datathe effects of that antiandrogen. Were also looking forward to getting their hormone-nave data, which is also going to come forth. Theres a trial where investigators are combining it with chemotherapy. So its pretty new; its the new agent, but Im feeling more and more comfortable with it.

What are the data supporting the use of the 3 newest agentsapalutamide, enzalutamide, and darolutamidein this setting?

My impression of the NCCN [National Comprehensive Cancer Network] guidelines is that theyre there to help us get through the insurance, because most of us are familiar with the datasets. And here [with] a PSA doubling time of less than 2 months in a man who has, by conventional imaging criteria, negative disease, you can use either apalutamide, darolutamide, [or] enzalutamideall category 1 [recommendations].1 But theyre also leaving open the option for other secondary hormonal therapy, allowing for older agents, which I think is not fair in view of all primary and secondary end points being met.

All 3 trialsSPARTAN [NCT01946204], PROSPER [NCT02003924], and ARAMIS [NCT02200614]were identical, with a primary end point looking at metastasis-free survival [MFS] of the agent plus ADT versus placebo, and secondary end points including progression-free survival [PFS], local progression, quality of life, and OS. That was [not a] secondary end point for a lot of the physicians. They still held [off] on it until they heard the final OS data. My prior chair would say, If Im going to treat a patient with an agent for 3 extra years, I need to make sure Im not compromising his quality of life or making his other morbidities worse. But there was a point in the SPARTAN trial [of apalutamide and ADT versus ADT and placebo in patients with nonmetastatic CRPC] that was important for me. It was the only [trial] that looked at the PFS2, which essentially compared starting earlier versus starting later and showed that starting earlier is better.

I think, in the interest of science, we should not stick with, This is what the SPARTAN trial says, this is what the PROSPER trial says, this is what ARAMIS trial says. We have 11 phase 3 trials across the board, across the cancer with novel androgen signaling inhibitors that are all positive. There has been no negative trial, which is phenomenal. The data is superimposable. You cant see a big difference in the efficacy. For efficacy assessment, I dont see a difference between the agents, and I use the datasets across the board. I think they are supportive of each other rather than antagonizing each other.

The [SPARTAN] results are old news now. There was a phenomenal difference in MFS that exceeds the 2-year mark [median MFS, 40.5 months with apalutamide versus 16.2 months without; HR, 0.28; 95% CI, 0.23-0.35; P<.001].2

The new finding that was reported at the [2020] ASCO meeting [was OS], and it was a poster discussion for all 3 [trials]. I like that they made them poster discussions rather than making them big oral discussions. They left oral discussions for more innovative things, [such as] the trials that we do with finding prescriptive markers. A lot of people complained that this was a big deal and should have been more showcased, but I think the fact that they were lumped together and discussed as a success for novel androgen signaling inhibitors is enough, and now we all would agree that their use in this space is valid. The main concern is finding these patients. The OS [had] about a median difference of a little over a year, which is not trivial, for the apalutamide [73.9 versus 59.9 months with ADT/placebo; HR, 0.78; 95% CI, 0.64-0.96; P=.0161].3

I was not involved in the SPARTAN or the ARAMIS trials, but I am an investigator on the PROSPER trial [of enzalutamide and ADT versus ADT and placebo in patients with nonmetastatic CRPC], and I was [included] in this New England Journal of Medicine paper that came out where we showed an OS benefit.4 [The design of the PROSPER trial was] exactly like SPARTAN.

Similar data [were] originally presented. OS difference looking at a year again [67.0 months with enzalutamide vs 56.3 months without; HR, 0.73; 95% CI, 0.61-0.89; P<.001]. The analysis that we saw on SPARTAN is the final analysis with the longest follow-up, but this is not far behind, [with] 48 months of median follow-up.

The ARAMIS trial [of darolutamide and ADT versus ADT and placebo in patients with high-risk nonmetastatic CRPC,] was the one that took us by surprise, because a lot of us were not familiar with this agent. I was seeing it in the background when it was developed, and I could hear Karim Fizazi, MD, PhD, whos a good friend, speaking about it. And I [said], We already have 3, what is this extra fourth going to come through with? And it turns out that they were right in pursuing it. Because they did exactly the same trial as the previous [trials of the other androgen signaling inhibitors], but with an agent that had all the prerequisites to be potentially safer, and they delivered.

The MFS with a short median follow-up [of 17.9 months], looking at about 2 years of difference of MFS [40.4 months with darolutamide versus 18.4 months with placebo], a hazard ratio of 0.41 [95% CI, 0.34-0.50; P<.0001]. Just as a reminder, for the other 2, it was about 0.3. Some people have commented on this, but I would not be able to compare.5

Now, their secondary end points were [more] defiant. At the first presentation, the OS was already starting to look good [with a hazard ratio of 0.71 (95% CI, 0.50-0.99; P<.045)]. It had not [yet] met their threshold, but it was close, and there was a short follow-up compared [with] the other trials.

The time to progression data [show a median time to pain progression of 40.3 months with darolutamide vs 25.4 months without (HR, 0.65; 95% CI, 0.53-0.79; P<.0001)]the other 2 trials also had similar data, which, as I see it, are supportive of each other rather than the inverse. This, for our patients, is a big deal.

Their PFS data [showing a median PFS of 36.8 versus 14.8 months (HR, 0.38; 95% CI, 0.32-0.45; P<.0001)] confirm what I said: superimposable MFS to PFSreinforcing the fact that the addition of a drug [such as] darolutamide, that seems to be safer, adds to these patients more time without need for further interventions and amounts to about 2 years.

The OS at a median follow-up of 29.1 months [was not reached in either arm]; its rather early compared [with] the rest but an obvious improvement here. The hazard ratio was around 0.69 and a P value of 0.003.6 So positive OS data for all 3 trials.

How do the safety profiles of these 3 agents compare?

[In terms of] adverse event reporting [from the PROSPER trial], the main concern, according to them, seems to be grade 3 and above hypertension and some fatigue. I would not pay a lot of attention to what is over grade 3 because when I use a drug for 2 to 3 years, for me even grade 1 and 2 matters. It makes absolute sense to use the least-compromising agent.4

Now, the [ARAMIS safety profile] the winner. They had little adverse events that are treatment related [with darolutamide] [TABLE].5 Its impressive if you look at it versus placebo. And if you want to look at a difference thats at least 2%, I see almost nothing. Its impressive.

When we were working on apalutamide, I got excited because I saw for the first time that 15% of patients were getting a weight decrease. If you look at the data from SPARTAN, it shows up. If you see [the data with] darolutamide, its 3.6%. We started doing some measurements, and its [because of] loss of muscle, and it adds on to the CNS effects. So the falls are not just a result of the CNS effect; its also a lot of muscle weakness, as well.

Overall, how do these 3 trials and drugs compare?

Of course, we shouldnt be [comparing these 3 trials] officially. But there is really no difference between the 3 trials when it comes to the primary and secondary end points. The only difference between the 3 trials with regard to their contact was that, in the apalutamide trial, patients came every month; in the other 2, it was every 4 months. But for MFS and OS, theres no difference between them. They had close hazard ratios.

So we have all [these] agents approved at this pointabiraterone acetate, enzalutamide, apalutamide, and darolutamide. Abiraterone is approved for the hormone-nave metastatic setting, and its also approved for metastatic CRPC; enzalutamide for hormone-nave and nonmetastatic and metastatic CRPC; apalutamide for nonmetastatic CRPC and hormone-nave; and darolutamide for nonmetastatic CRPC. I would argue that for me, these 4 agents have equivalence in their efficacy, and its more a matter of safety.

How does the use of novel imaging affect the duration of treatment and quality of life of these patients?

With the advent of enhanced androgen signaling in the hormone-nave space, I feel that were adding these drugs for an indefinite amount of time. Were going to try to do that with finite-duration hormones, so that we may get the opportunity to prolong the quality of life of the patients. But, as its standing right now, if you do a PET early on in the disease, you may end up treating those men indefinitely.

We know well that if you dont take care to look out for cardiovascular morbidity, bone health, and the like, especially in the older men, you can get a tradeoff thats not to the benefit of the patient. Its a big discussion. But I sometimes say that 1 option is to be more diligent about making sure that the patients are followed at least by their primary care physicians and their cardiologist more carefully.

What are some of the drugs that should be avoided during use with these agents?

Thankfully most of us use electronic prescribing, so we see the drug-drug interactions show up. I dont think we can ever remember all of that by heart.

References:

1. NCCN Clinical Practice Guidelines in Oncology: Prostate cancer. Version 2.2020. May 21, 2020. Accessed August 17, 2020. https://bit.ly/32pmz7H

2. Smith MR, Saad F, Chowdhury S, et al. Apalutamide (APA) and overall survival (OS) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): updated results from the phase III SPARTAN study. Ann Oncol. 2019;30(suppl 5):v325. doi:10.1093/annonc/mdz248

3. Small EJ, Saad F, Chowdhury S, et al. Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC). J Clin Oncol. 2020;30(suppl 15):5516. doi:10.1200/JCO.2020.38.15_suppl.5516

4. Sternberg CN, Fizazi K, Saad F, et al; PROSPER Investigators. Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2020;382:2197-2206. doi:10.1056/NEJMoa2003892

5. Fizazi K, Shore ND, Tammela TL, et al; ARAMIS Investigators. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2019;380:1235-1246. doi:10.1056/NEJMoa1815671

6. Fizazi K, Shore ND, Tammela T, et al. Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC). J Clin Oncol. 2020;38(suppl 15):5514. doi:10.1200/JCO.2020.38.15_suppl.5514

Read this article:
Efstathiou Compares the Efficacy and Safety of AR Inhibitors in Nonmetastatic CRPC - Targeted Oncology

Recommendation and review posted by Bethany Smith

Global In Vitro Fertilization (IVF) Market report an in depth study of various aspects of the worldwide Market. It shows the steady growth in market in spite of the fluctuations and dynamic market trends. The rising technology in Market is additionally delineated during this analysis report. Factors that are boosting the expansion of the market and giving a positive push to thrive within the international market is explained well. It includes a meticulous analysis of market trends, market shares and revenue growth patterns and also the volume and price of the market. Its conjointly supported a meticulously structured methodology. These strategies facilitate to analyze markets on the premise of thorough research and analysis.

Access Free Sample Copy of In Vitro Fertilization (IVF) Market Report https://calibreresearch.com/report/global-in-vitro-fertilization-ivf-market-1223#request-sample

In this analysis report, the world In Vitro Fertilization (IVF) Market focuses on the key players that are in operation within the global market and their competitive landscape present within the worldwide. The In Vitro Fertilization (IVF) report includes an inventory of initiatives taken by the businesses within the past years in conjunction with those, that are doubtless to happen within the coming back years. Analysts have conjointly created a note of their enlargement plans for the close to future, monetary analysis of those firms and their analysis and development activities. This analysis report includes a whole dashboard read of the worldwide In Vitro Fertilization (IVF) market, that helps the readers to look at an in-depth data regarding the report.

NOTE: Our reports include the analysis of the impact of COVID-19 on this industry. Our new sample is updated which correspond in new report showing impact of Covid-19 on Industry trends. Also we are offering 20% discount

The analysis report summarizes companies from many different regions. This In Vitro Fertilization (IVF) Market report has been combined with a spread of market segments like applications, finish users and sales. Specialise in existing market research and future innovation to produce higher insight into your business. This study includes subtle technology for the market and numerous views of assorted industry professionals. In Vitro Fertilization (IVF) Market is that the arena of accounting distressed with the outline, analysis and news of monetary dealings touching on a business. This includes the coaching of monetary statements offered for public ingesting. The service involves temporary, studying, checking and news of the monetary contacts to collecting activities and objects. It conjointly involves checking and creating monetary declarations, scheming accounting systems, rising finances and accounting consultive.

Do You Have Any Query or Specific Requirement? Ask to Our Industry Expert

Global Major Market Players indulged in this report are:

AVA-PETER CLINICMD MEDICAL GROUP INVESTMENTS PLC (MD MEDICAL GROUP)IVF RUSSIA (THE INTERNATIONAL CENTRE OF THE REPRODUCTIVE MEDICINES)

The In Vitro Fertilization (IVF)The In Vitro Fertilization (IVF) Market market report is segmented into following categories:

End User segmentFertility ClinicsHospitalsSurgical CentersClinical Research InstitutesCycle Type segmentFresh IVF cycles (Non-donor)Thawed IVF cycles (Non-donor)Donor Egg IVF CyclesType segmentNon-ICSI IVF CyclesICSI-assisted IVF CyclesDrug segmentClomiphene CitrateAromatase InhibitorsGonadotropins & Gonadotropin-releasing HormoneFollicle-stimulating HormoneProgesteroneOthersMode of Administration segmentOralInjectableVaginal

The report offers in-depth assessment of the expansion and different aspects of the In Vitro Fertilization (IVF) market in necessary regions, together with the U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, Asian nation, Taiwan, geographic area, United Mexican States and Brazil, etc. Key regions lined within the report are North America, Europe, Asia-Pacific and geographical region.

This In Vitro Fertilization (IVF) Market research report identifies numerous key players of the market. It helps the reader perceive the ways and collaborations that players are that specialize in combat competition within the market. The excellent report provides a major microscopic cross-check the market. The reader will establish the footprints of the players by knowing regarding the worldwide revenue of players, the worldwide worth of players and production by players throughout the forecast amount.

Browse In Vitro Fertilization (IVF) Market Report for Better Understanding: https://calibreresearch.com/report/global-in-vitro-fertilization-ivf-market-1223

For a more robust understanding of the worldwide market, analysts have metameric the worldwide In Vitro Fertilization (IVF) market supported application, sort and regions. Every phase provides a transparent image of the aspects that are doubtless to drive it and also the ones expected to restrain it. The segment-wise rationalization permits the reader to induce access to explicit updates regarding the worldwide In Vitro Fertilization (IVF) market. Evolving environmental issues, dynamic political situations and differing approaches by the govt. towards regulative reforms have conjointly been mentioned within the In Vitro Fertilization (IVF) analysis report 2020-2026.

Major factors lined within the international In Vitro Fertilization (IVF) marketing research Report 2020-2026

Global In Vitro Fertilization (IVF) Market Outlook and Summary.Economic Impact on the Industry.Global In Vitro Fertilization (IVF) Market Competition in terms of players.Global In Vitro Fertilization (IVF) Market Production, Revenue (Value) by geographical segmentation.Global In Vitro Fertilization (IVF) Market Production, Revenue (Value), worth Trend by sort.Global In Vitro Fertilization (IVF) market research by Application.Global In Vitro Fertilization (IVF) Market price Investigation.Global In Vitro Fertilization (IVF) Market Industrial Chain, material sourcing strategy and Downstream patrons.Marketing Strategy comprehension, Distributors and Industryrs.Global In Vitro Fertilization (IVF) Market Study on marketing research Factors.Global In Vitro Fertilization (IVF) Market Forecast 2020-2026.

See more here:
In Vitro Fertilization (IVF) Market 2020-2026: AVA-PETER CLINIC, MD MEDICAL GROUP INVESTMENTS PLC (MD MEDICAL GROUP), IVF RUSSIA (THE INTERNATIONAL...

Recommendation and review posted by Bethany Smith

Incorporating healthy fats is beneficial for weight loss, as well as for your overall health.

Image Credit: autumnhoverter/iStock/GettyImages

If you're old enough to recall the '80s and '90s, you probably remember it as a time of low-fat everything. Dietary fats, regardless of type unsaturated, saturated, omega-3s or trans fats were, for the most part, lumped together and seen as problematic when it came to weight loss and heart health.

It took us some time (read: a few decades) to understand that this line of thinking wasn't entirely accurate and that avoiding all fats was hurting our hearts and waistlines.

Fast forward to today where the keto diet is king, and it appears we're now living on the opposite end of the spectrum. We've gone from limiting fats as much as possible, to a trendy diet that is about 75 percent fat, 20 percent protein, and 5 percent carbohydrates.

So, where do fats belong when it comes to managing our weight and overall health?

The truth is, somewhere in the middle, and the science on this will continue to evolve annoying, I know. The current Institute of Medicine guidelines, based on available science, recommend a diet that is 20 to 35 percent fat, 45 to 65 percent carbs and 10 to 35 percent protein.

Did you know that keeping a food diary is one of the most effective ways to manage your weight? Download the MyPlate app to easily track calories, stay focused and achieve your goals!

Dietary Fat and Weight Loss

Fats are a crucial part of our diet. They are a source of energy and they help our bodies produce hormones and better absorb fat-soluble nutrients like vitamins A, D, E and K, as outlined by the American Heart Association.

A gram of fat (regardless of type) has 9 calories. They're more calorically dense than protein (4 calories per gram) and carbs (also 4 calories per gram). This is one of the reasons why we pursued low-fat diets long ago.

But it's important to keep in mind that eating an excess of calories, regardless of the macronutrient source, will lead to weight gain, and be aware that fats are actually beneficial for weight loss. Here's why:

Dietary Fats Slow Down Digestion

Dietary fats naturally slow "gastric emptying," i.e., the time it takes for food to leave your stomach and continue its course through your GI tract, according to the July 2014 issue of Today's Dietitian.

We know that foods that take a while to digest leave us feeling fuller longer. So, adding a little bit of fat to your meal, like olive oil on a salad, or avocado in your smoothie, will help to slow down how quickly you digest your meal.

Furthermore, research shows adding fiber slows down the digestion of fat even further.

Dietary Fats Favorably Affect Hunger Hormones

There's a growing body of research looking at the effect different types of fat have on various hunger hormones and satiety levels.

A March 2019 study published in Appetite found that eating meals higher in polyunsaturated fats (PUFAs) led to a greater decrease in ghrelin (a hormone that triggers hunger) and higher CCK levels (a hormone that suppresses hunger) compared to monounsaturated fat. The diet high in PUFAs also resulted in lower hunger ratings, although there was no difference between the amount of calories consumed and the reported feelings of fullness.

4 Fats to Add When Youre Trying to Lose Weight

Adding some avocados to your tacos will help you digest the meal slower.

Image Credit: sveta_zarzamora/iStock/GettyImages

What makes avocados so special when it comes to weight loss? It's the healthy fat and fiber combo. A serving of avocado (one-third of the fruit) has 4.5 grams of fiber and 9 grams of fat, according to the USDA.

If you pair the avocado with a salad, chips or tacos, the added fat will help to slow down the digestion of the meal and the grams of fiber slow it down even further. The only caveat is portion control. Avocado is good, yes, but polishing off a bowl of guac isn't going to help your cause.

Yes, eating fish is great for your health and waistline but salmon (and a few other fish like tuna and sardines) may have the upper hand. These specific types of fish are rich in omega-3 fatty acids and it turns out, these fats may help improve leptin resistance, according to a July 2015 article published in Today's Dietitian.

If you are carrying some extra weight, chances are you also have chronic inflammation and it's the inflammatory chemicals that cause our body to be less sensitive to leptin, a hormone that decreases our food intake and regulates our metabolism. Omega-3s however, can help make your body less resistant to leptin, allowing it to do its job.

Nuts are a good source of healthy fats they can be up to 80 percent fat, per the Mayo Clinic. And, all tree nuts are good for us. Eating nuts is great for our heart because they help to lower LDL cholesterol levels and reduce inflammation linked to cardiovascular disease.

But walnuts are a standout because they're unique in that they contain a solid dose of omega-3s, according to California Walnuts. This also means they're rich in PUFAs, which we know has been shown to favorably alter our hunger hormone levels as well.

A drizzle of olive oil on your salad may help with your weight-loss efforts.

Image Credit: Nicholas77/iStock/GettyImages

It may seem counterintuitive to add oil to your salad if you're trying to lose weight, but olive oil may actually help you better manage your body weight. It is a staple of the Mediterranean diet after all, which has been touted as one of the healthiest and most researched diets that we can follow.

Researchers looked at 11 different randomized clinical trials addressing olive oil and weight management and concluded that a diet enriched with olive oil led to a greater reduction in weight than a control diet without, according to a November 2018 meta-analysis published in Revista Espaola de Salud Pblica.

2 Fats to Limit if Youre Trying to Lose Weight

The biggest thing that will lead to weight gain is overeating no matter the source of calories.

That said, we know some foods are beneficial for our health while others are not. Trans fats and saturated fats provide no benefit to our diet and can do more harm than good, although more research is coming out on the effects of different saturated fats stay tuned!

Here's the deal: Trans fats have no redeeming qualities, so much so that the U.S. Food and Drug Administration has required that the artificial fat be removed from all processed foods. While the amount in our food supply has been cut back drastically, some still exists, according to the Mayo Clinic.

Margarine, refrigerated dough, baked goods and fried foods like French fries and doughnuts may all contain trans fats.

You won't find trans fats in healthy fat sources of food like chia seeds and almonds, but you may find them in ultra-processed junk food that is typically high in refined grains, too. These are the types of foods you'll want to limit if you're trying to lose weight.

If you're trying to lose weight, chances are you're watching what you eat and trying to eat less. When we do that, it's especially critical that we focus on nutrient-dense foods so that we get all of the nutrients that we need.

By limiting the saturated fat in our diet which we know provides no benefit we leave room for more beneficial sources of fat like mono- and poly-unsaturated fats.

You'll find saturated fat in fatty meats, fried food and butter.

Additionally, saturated fats may increase inflammation by kicking on a pathway that triggers what's called obesity-induced inflammatory response, according to an April 2018 study published in Nutrients. So, if you're overweight, eating foods high in saturated fat may trigger a greater inflammatory response in your body.

See the original post:
Trying to Lose Weight? Here Are 4 Fats to Enjoy and 2 to Avoid - LIVESTRONG.COM

Recommendation and review posted by Bethany Smith

Blood Testing Market Scope of the Report:

Factors and Blood Testing Market execution are analyzed using quantitative and qualitative approaches to give a consistent picture of current and future trends in the boom. The study also allows for a detailed market analysis focused primarily on geographic locations. The Global Blood Testing Market Report offers statistical graphs, estimates, and collateral that explain the state of specific trade within the local and global scenarios.

The worldwide market for Blood Testing is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2025, from xx million US$ in 2018, according to a new study.

This report focuses on the Blood Testing in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

For more insights into the Market, request a sample of this report (Including Full TOC, List of Tables & Figures, Chart) @ https://www.researchmoz.com/enquiry.php?type=S&repid=2736902&source=atm

segment by Type, the product can be split intoGlucoseLipidBUNA1CCRPVitamin DALTASTThyroid Stimulating HormoneMarket segment by Application, split intoHospitalsClinic and Diagnostic CentersOthers

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

For Information On The Research Approach Used In The Report, Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2736902&source=atm

Reasons to Purchase this Blood Testing Market Report:

* Analyzing the outlook of the market with the recent trends and SWOT analysis

* Market dynamics scenario, along with growth opportunities of the market in the years to come

* Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and non-economic aspects

* Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.

* Market value (USD Million) and volume (Units Million) data for each segment and sub-segment

* Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years

* Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

* 1-year analyst support, along with the data support in excel format.

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2736902&licType=S&source=atm

The Blood Testing Market report has 150 tables and figures browse the report description and TOC:

Table of Contents

1 Study Coverage

1.1 Blood Testing Product

1.2 Key Market Segments in This Study

1.3 Key Manufacturers Covered

1.4 Market by Type

1.4.1 Global Blood Testing Market Size Growth Rate by Type

1.5 Market by Application

1.5.1 Global Blood Testing Market Size Growth Rate by Application

2 Executive Summary

2.1 Global Blood Testing Market Size

2.1.1 Global Blood Testing Revenue 2014-2025

2.1.2 Global Blood Testing Production 2014-2025

2.2 Blood Testing Growth Rate (CAGR) 2019-2025

2.3 Analysis of Competitive Landscape

2.3.1 Manufacturers Market Concentration Ratio (CR5 and HHI)

2.3.2 Key Blood Testing Manufacturers

2.3.2.1 Blood Testing Manufacturing Base Distribution, Headquarters

2.3.2.2 Manufacturers Blood Testing Product Offered

2.3.2.3 Date of Manufacturers Enter into Blood Testing Market

2.4 Key Trends for Blood Testing Markets & Products

3 Market Size by Manufacturers

3.1 Blood Testing Production by Manufacturers

3.1.1 Blood Testing Production by Manufacturers

3.1.2 Blood Testing Production Market Share by Manufacturers

3.2 Blood Testing Revenue by Manufacturers

3.2.1 Blood Testing Revenue by Manufacturers (2019-2025)

3.2.2 Blood Testing Revenue Share by Manufacturers (2019-2025)

3.3 Blood Testing Price by Manufacturers

3.4 Mergers & Acquisitions, Expansion Plans

More Information.

For More Information Kindly Contact:

ResearchMoz

Mr. Rohit Bhisey,

90 State Street,

Albany NY,

United States 12207

Tel: +1-518-621-2074

USA-Canada Toll Free: 866-997-4948

Email: [emailprotected]

The rest is here:
Blood Testing Market Share, Growth by Top Company, Region, Applications, Drivers, Trends & Forecast to 2025 - The Daily Chronicle

Recommendation and review posted by Bethany Smith

Rising number of corona virus cases has impacted numerous lives and led to numerous fatalities, and has affected the overall economic structure globally. The Adenomyosis Treatment has analyzed and published the latest report on the global Adenomyosis Treatment market. Change in the market has affected the global platform. Along with the Adenomyosis Treatment market, numerous other markets are also facing similar situations. This has led to the downfall of numerous businesses, because of the widespread increase of the number of cases across the globe.href=mailto:[emailprotected]>[emailprotected] or call us on +1-312-376-8303.

Request Free Sample Copy of Adenomyosis Treatment Market Research [emailprotected] https://cognitivemarketresearch.com/pharma-%26-healthcare/adenomyosis-treatment-market-report

The major players in the Adenomyosis Treatment market are Bayer AG, Ferring B.V, Johnson & Johnson, Novartis, Merck, Pfizer, Speciality European Pharma . Some of the players have adopted new strategies to sustain their position in the Adenomyosis Treatment market. A detailed research study is done on the each of the segments, and is provided in Adenomyosis Treatment market report. Based on the performance of the Adenomyosis Treatment market in various regions, a detailed study of the Adenomyosis Treatment market is also analyzed and covered in the study.

Report Scope:Some of the key types analyzed in this report are as follows: Anti inflammatory drugs, Hormone medications, Other

Some of the key applications as follow: Hospital, Clinic, Others

Following are the major key players: Bayer AG, Ferring B.V, Johnson & Johnson, Novartis, Merck, Pfizer, Speciality European Pharma

An in-depth analysis of the Adenomyosis Treatment market is covered and included in the research study. The study covers an updated and a detailed analysis of the Adenomyosis Treatment market. It also provides the statistical information of the Adenomyosis Treatment market. The study of the report consists of the detailed definition of the market or the overview of the Adenomyosis Treatment market. Furthermore, it also provides detailed information for the target audience dealing with or operating in this market is explained in the next section of the report.

Read Detailed Index of full Research Study @: https://cognitivemarketresearch.com/pharma-%26-healthcare/adenomyosis-treatment-market-report#download_report

The report also provides detailed information on the research methodologies, which are used for the analysis of the Adenomyosis Treatment market. The methods are covered in detail in this section of the report. For the analysis of the market, several tools are used for the extraction of the market numbers. Among the several tools, primary and secondary research studies were also incorporated for the research study. These were further analyzed and validated by the market experts, to increase precision and make the data more reliable.

Moreover, the report also highlights and provides a detailed analysis of the drivers, restrains, opportunities, and challenges of the Adenomyosis Treatment market. This section of Adenomyosis Treatment market also covers the updated information, in accordance with the present situation of the market.

According to the estimation and the analysis of the market, the Adenomyosis Treatment market is likely to have some major changes in the estimated forecasts period. Moreover, these changes can be attributed to the changes due to economic and trading conditions across the globe. Moreover, several market players operating in the Adenomyosis Treatment market will have to strategically change their business strategies in order to survive in the market.

If Any Inquiry of Adenomyosis Treatment Report @: https://cognitivemarketresearch.com/pharma-%26-healthcare/adenomyosis-treatment-market-report#download_report

Reasons for Buying this Adenomyosis Treatment Report1. Adenomyosis Treatment market advertise report helps with understanding the Basic product segments alongside likewise their potential future.2. This global Adenomyosis Treatment report offers pin-point evaluation for changing competitive dynamics.3. The Adenomyosis Treatment market supplies pin point analysis of changing competition dynamics and keeps you in front of competitors4. Original images and illustrated a SWOT evaluation of large segments supplied by the Adenomyosis Treatment market.5. This report supplies a forward-looking perspective on different driving factors or controlling Adenomyosis Treatment market gain.6. This report assists to make wise business choices using whole insights of the Adenomyosis Treatment and also from creating a comprehensive evaluation of market sections.Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

*If you have any special requirements, please let us know and we will offer you the report as you want Click Here>Download Customized Sample Report of Adenomyosis Treatment Market Report 2020 (COVID-19 Impact Analysis Updated Edition May 2020)

About Us: Cognitive Market Research is one of the finest and most efficient Market Research and Consulting firm. The company strives to provide research studies which include syndicate research, customized research, round the clock assistance service, monthly subscription services, and consulting services to our clients. We focus on making sure that based on our reports, our clients are enabled to make most vital business decisions in easiest and yet effective way. Hence, we are committed to delivering them outcomes from market intelligence studies which are based on relevant and fact-based research across the global market.

Contact Us: +1-312-376-8303Email: [emailprotected]Web: https://www.cognitivemarketresearch.com

**********Download the Entire Report*************************************************https://cognitivemarketresearch.com/pharma-%26-healthcare/adenomyosis-treatment-market-report

The rest is here:
In Depth Analysis and Survey of COVID-19 Pandemic Impact on Global Adenomyosis Treatment Market 2020 Key Players Bayer AG, Ferring BV, Johnson &...

Recommendation and review posted by Bethany Smith

My working title for this story was Fat at 50, Forever, and you can hardly blame me. While it was definitely tongue-in-cheek, for those of us whove gained a few pounds in midlife, maintaining a healthy size becomes and theres no way to sugar-coat it increasingly difficult. As you age, you put on weight, says the founder of the diagnostic clinic Viavi:be Dr Sabine Donnai, who specialises in health and exercise programmes for the over fifties. And thats if youre just standing still, not eating, not doing anything, just purely because your metabolism goes down each year.

Tempting as it is to accept this as an unavoidable part of getting older, there is (vanity aside) good reason for resisting this seemingly inexorable increase. As well as the surface weight were amassing, were also accumulating visceral fat, which surrounds our organs and stops them functioning as well as they should, which leads to a shorter lifespan.

Women have it twice as bad: along with the ageing process, during which the body swaps muscle for fat, we have the menopause to deal with. The loss of oestrogen has a particular effect on the way your fat is distributed, says Dr Donnai. Firstly, when oestrogen drops, you get mood swings, and frequently you overeat to compensate. You sleep badly as your progesterone drops, and your stress levels rise, often because its easy at this age to lose a sense of purpose especially if youve had children and theyre growing up and relying on you less.

Additionally, your body stores fat differently, as its lipoprotein lipase (which sits on the surface of the fat cells, pulling in fat from the blood) goes into overproduction, no longer kept in check by the now declining oestrogen. If the fat gets pulled into a muscle cell, it gets burnt off as fuel; but if it gets pulled into a fat cell, it just makes the fat cell bigger. You get the idea.

At this point, youre probably expecting a paragraph starting with the word fortunately, followed by a quick-fix diet with, quite possibly, some new gadget or machine promising that the whole sorry situation will be resolved in no time. Im sorry to disappoint. You need to get into the gym and lift weights, says Dr Donnai matter-of-factly. I know this is often alien to mature women, who are more used to yoga and some Pilates, both of which play a part, but its weights that will slow down the ageing process.

The physiological explanation behind this is that when you start training and lifting weights that feel like theyre too much for you, your body responds by making more muscle, in order to prevent what it perceives as damage. It stimulates a growth hormone, which in turn stimulates testosterone, and lifting that weight each time causes your metabolism to speed up. The lipoprotein lipase now pulls the fat into muscle cells, and because you have more muscle now anyway, thanks to lifting weights, your basic metabolic rate goes up, so you can eat without gaining weight, or lose weight if you eat slightly less.

Are weights the only option? Women really need to create high muscular overload on two fronts: to burn more calories, and raise the metabolism; but also to maintain bone density, says Matt Roberts, founder of the Matt Roberts Evolution personal training gym. When you stress the muscles, the tendons which are attached to the bone pull on it; the bone thinks it needs assistance and stores more calcium, and your bone density increases. High-impact exercise, going for a run, jumping, landing and moving, all also increase bone density. The impact of boxing is really good for bone density in the upper body, whereas running is good for the lower body. But you need a strategy in place for injury prevention this is where the yoga and Pilates come in as they create elasticity in the muscle tissue around the joints.

Sooner rather than later, we also have to address diet. To kick-start weight loss before a surf trip on which I didnt want to be carrying excess pounds, I embarked on a metabolic balancing diet under the guidance of Amanda Griggs at the Khera-Griggs clinic. I lost 8lbs in two weeks, and Id do it again, but perhaps only once a year it was tough.

You have to look at taking out starches and carbohydrates, rethink your portions, says Griggs. You have to realise, This is my meal. If that sounds a little grim, it has the advantage of reintroducing discipline. With a ban on snacking between meals, the diet which is restrictive for a fortnight but moves on to a maintenance plan thats all about mindful eating is healthy and delivers results. My BMI dropped to bang-on healthy. Of course, how you keep up those results is another matter. Youre quite disobedient, says Griggs, who guided me through the two weeks with plenty of stern, kind and highly motivating WhatsApp messages. Sometimes you only ate two meals a day, and Im not sure you always stuck to the quantities of protein you needed.

Roberts also homes in on protein. If you focus on eating enough protein, you just wont have the appetite for carbs. A womans protein intake is woefully low, he says. Government guidelines suggest 45g of protein for a 60kg woman, but Roberts explains, One egg is about 5g. So shifting away from carbs and loading up on beans and quinoa or eating sardines, as theyre high in calcium, will help control your blood sugar, raise your metabolism, and activate fat burn.

As well as advising abstaining from alcohol It gives you nothing other than a hangover and strips away Vitamin B13, which is vital for brain function hes also a fan of intermittent fasting. As women get older, they tend to think they need to eat less, and go on extreme low-calorie diets, but they dont work. You just add on more weight than you did before. Women have greater levels of visceral fat if you fast for 16 hours (from around 8pm until midday) for two to four days a week, for up to four weeks, and for the rest of the week take out the obvious foods that build up blood sugar, and increase protein, your body gets into a state of ketosis (where your metabolism is more energised due to lower blood sugar levels) and youll be burning away your visceral fat.

It all sounds easy enough, but as an inveterate carb-loading snacker who has eaten two and a half croissants while writing this I apparently still have a way to go.

More from British Vogue:

More here:
Whats Really The Best Way To Maintain A Healthy Weight Over 50? - British Vogue

Recommendation and review posted by Bethany Smith

The report gives a complete investigation of the Controlled Intelligent Packaging, Preservation and Shelf-Life Extension industry and key market improvements. The exploration record comprises of past and figure showcase data, prerequisite, territories of use, value strategies, and friends portions of the main organizations by topographical district. The Controlled Intelligent Packaging, Preservation and Shelf-Life Extension market report separates the market size, by volume and worth, depending upon the kind of utilization and area.

Request sample copy of this report athttps://www.precisionbusinessinsights.com/request-sample?product_id=22532

Some of the players in Controlled Intelligent Packaging, Preservation and Shelf-Life Extension Market are Cargill Inc. (U.S),Nestl (Switzerland),DuPont (U.S),Tetra Pak (Switzerland),International Paper Co (U.S),Crown Holdings Inc. (U.S),Bemis Company Inc. (U.S),Tyson Foods Inc. (U.S)

With everything taken into account, the Controlled Intelligent Packaging, Preservation and Shelf-Life Extension market report offers inside and out profile and information data life structures of driving Controlled Intelligent Packaging, Preservation and Shelf-Life Extension organizations.

The Controlled Intelligent Packaging, Preservation and Shelf-Life Extension market report presents a point by point estimation of the market through complete appraisal, fantastic experiences, and bona fide expectations managing the Controlled Intelligent Packaging, Preservation and Shelf-Life Extension market size. It depends on attempted and tried methodologies alongside convictions in the event of the estimate made accessible. In this manner the nitty gritty investigation of Controlled Intelligent Packaging, Preservation and Shelf-Life Extension market fills in as a repository of examination and information for each part of the market, especially concerning nearby markets, innovation, classifications, and use.

The report involves the estimation of the Global Controlled Intelligent Packaging, Preservation and Shelf-Life Extension Market. The accompanying Industry is appeared to advance with a critical ascent in the Compound Annual Growth Rate (CAGR) during the conjecture time frame attributable to different elements driving the market.

Request Customization athttps://www.precisionbusinessinsights.com/request-customisation?product_id=22532

The extent of the report stretches out from market situations to similar valuing between significant players, cost and benefit of the predetermined market areas. The numerical information is upheld up by factual apparatuses, for example, SWOT investigation, Porters Five Analysis, PESTLE examination, etc.

Key Features of the Report:

There are 10 Chapters to deeply display the Controlled Intelligent Packaging, Preservation and Shelf-Life Extension market.Chapter 1 to analyze the top manufacturers of Controlled Intelligent Packaging, Preservation and Shelf-Life Extension, with sales, revenue and price of Controlled Intelligent Packaging, Preservation and Shelf-Life Extension in 2020 and 2026.

Chapter 2, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2020 and 2026.

Chapter 3, to show the global market by regions, with sales, revenue and market share of Controlled Intelligent Packaging, Preservation and Shelf-Life Extension, for each region, from 2020 and 2026.

Chapter 4, 5, 6 and 7 to analyze the key regions, with sales, revenue and market share by key countries in these regions.

Chapter 8 and 9, to show the market by type and application, with sales market share and growth rate by type, application, from 2020 and 2026.

Chapter 10 Controlled Intelligent Packaging, Preservation and Shelf-Life Extension market forecast, by regions, type and application, with sales and revenue, from 2020 and 2026.

About Us:

Precision Business Insights is one of the leading market research and management consulting firm, run by a group of seasoned and highly dynamic market research professionals with a strong zeal to offer high-quality insights. We at Precision Business Insights are passionate about market research and love to do the things in an innovative way. Our team is a big asset for us and great differentiating factor. Our company motto is to address client requirements in the best possible way and want to be a part of our client success. We have a large pool of industry experts and consultants served a wide array of clients across different verticals. Relentless quest and continuous endeavor enable us to make new strides in market research and business consulting arena.

Contact Us:

[emailprotected]

PH +1-866-598-1553

Read more:
Controlled Intelligent Packaging, Preservation and Shelf-Life Extension Market Will Generate Record Revenue by 2026 - The News Brok

Recommendation and review posted by Bethany Smith

My fasting blood glucose has been creeping up over several years. (My fasting blood sugar is around 110, and HbA1c=5.7; fasting insulin=3.1, triglycerides=91.) Recently, I tried a continuous glucose monitor for the first time, to see what I could learn about eating and exercise habits that affect my blood glucose. The experiment led me to some reading and thinking that was worthwhile, but the results themselves were disappointing, limited (first) by flaws in the technology and (second) by wide variability that I could not trace to any of the usual behavioral correlates.

Why concern ourselves with blood sugar?

Insulin is generated in the pancreas after we eat, with a cascade of effects on the body. The primary short-term effect is to prevent glucose levels in the blood from getting too high, by notifying the liver of the need to pull glucose out of the blood and store energy as fat.

Loss of insulin sensitivity is a primary hallmark of human aging. Most of the known life extension strategies in lab animals have to do with insulin in one way or another. For example, the worm genedaf-2is the worms only insulin receptor, and mutating (weakening) thedaf-2 gene doubles the worms lifespan. Life extension benefits of exercise and caloric restriction are thought to work, at least in part, through the insulin metabolism.

But glucose is also dangerous, and as we get older we are poisoned by excess sugar in the blood. High blood sugar leads to [list fromMayo Clinic]

So for long-term health, the name of the game is to keep blood sugar down with as little insulin as possible, hence preservation of insulin sensitivity is the target. Metformin is a well-studied drug for keeping blood sugar down without insulin. I have been taking it (irregularly) for the last several years, intermixed with berberine and Gynostemma(Chinese name: jiaogulan =).

This reasoning plus direct evidence for life extension in rodents and indirect evidence of life extension in humans has led me to take metformin, though it is not without side-effects.

Long-term effects of metformin

Metformin is a credible longevity drug, statistically associated with lower risk of cancer, heart disease and especially dementia in humans. Six years ago,this studylaid the foundation for metformin as a longevity drug with the claim that people taking metformin had lower all-cause mortality, despite the fact that a population of type-2 diabetics was being compared to a healthier population. This finding inspired Nir Barzilai to raise support for theTAME study.

But metformin has its risks. A long-time contributor to this site, Dr Paul Rivas pointed me to evidence thatmetformin can interfere with exercise metabolism. Paul notes his personal experience with loss of peak performance while taking metformin. My own experience is consistent with this, though I have never done a rigorous A/B comparison.This study, demonstrating a small but consistent decrease in peak performance, appears to me to be well-designed and analyzed. A plausible mechanism is the interference of metformin with mitochondrial function [ref,ref].This article claims that metformin suppresses synthesis of ATP, which is the reservoir of energy for immediate use in all cell types. Ben Miller has done the most direct and most recently relevant human experiments in this area and his findings suggest the intriguing possibility that metformin blocks exercise adaptations almost completely in about half of individuals, but not at all in the other half. (If you want to know which half youre in, youll have to wait for next years study.)

For the majority of Westerners who exercise little or not at all, metformin may show reduction in long-term risk of age-related disease; but there is no data I know of on the subset of people who do vigorous exercise, comparing metformin to no metformin. Does metformin block the health effects of exercise?Rhonda Patrick citescredible referenceson this subjectas fast as she can get the words out, and her conclusion is that exercise is a better anti-aging program than metformin, and you really cant have both.

Do glucose-control herbs also blunt the benefits of exercise?

I wrote a few years ago listingbotanical alternatives to metformin. Much less research has gone into these herbs, so we must think theoretically about interference with benefits of exercise.

Berberine works by a mechanism of action that overlaps metformin. Both metformin and berberine promote AMPK (which in turn promotes sugar burning). Both metformin and berberine inhibit mitochondrial Complex I (slowing the conversion of sugar to usable energy). There is tentative experimental evidence that (unlike metformin) berberine does not inhibit adaptations to exercise [ref,ref,ref].

Gynostemmais a Chinese herb popularized by Life Extension Foundation in their proprietary compound calledAMPK Activator. Inanimal modelsand in humans,Gynostemmasuppresses blood sugar and blood cholesterol. Like metformin and berberine, it works through AMPK,which appears to be a good thing. It isanti-inflammatory, and has a history in China as cancer therapy, supported bymouse andin vitrostudies. In rodent studies,Gynostemmahas a beneficial effect on strength and endurance [ref,ref,ref]. Theone studyIve found on human diabetes shows modest benefits after 12 weeks. The only counter-indication that I have seen is that itincreases insulin release (in vitro), which I believe to be pro-aging.

Is it more important to suppress postprandial spikes or to depress fasting glucose levels?

HbA1c is a standard blood test for diabetes. It isrelated to average blood glucoselevels over the previous 90 days (= the half-life of hemoglobin in the blood). But the glycation of hemoglobin (as measured by A1c) happenspredominantly during the brief glucose spikes, rather than the much longer periods of average glucose levels. So it might be fairer to say that A1c summarizes peak glucose events over a 90-day period. And we might guess that the long-term health risks of high blood sugar are similarly more sensitive to the peaks than to the average.

I believe that apoptosis is on a hair trigger as we age, and part of the reason for this is too much p53.This studylinks P53 activation to postprandial glucose spikes, rather than to high average glucose levels.This studylinks deterioration in endothelial function (related to arterial disease) with glucose spikes. The same paper lists ROS and oxidative stress as additional risks.

For a long while, it has been established that high fasting blood sugar is associated withcardiovascular risk. Of course, there is also association withobesity and T2 diabetes, but for these, it is natural to think of fasting blood sugar as the result, rather than the cause.

Chris Kressersays the best indicator of metabolic health is blood glucose levels 2 hours after a meal. If you can bring your blood glucose down to normal within 2 hours after eating your insulin sensitivity is good. For me, unmedicated, it was 3 hours after dinner, but less than 2 hours after breakfast. Either berberine or metformin tamed the after dinner spikes within 2 hours.

Kresser claims that these guidelines from the American Diabetes Association are not strict enough, and that statistics show increased future risk of diabetes even for people in the ADA normal range. But he citesPetro Dobromylskyj, who makes an exception for anyone on a low-carb diet (how low isnt specified). Paradoxically, low-carb diets are claimed to be healthy, even though they decrease insulin sensitivity. I have been unable to make sense of this.

Kresser emphasizes that all numbers should be interpreted in the context of a persons other lifestyle and health indicators. In people who are active and not overweight, he is not inclined to worry about statistics in the prediabetic range. (I take comfort in this personally, and who can say if Im fooling myself?) But I can learn something from the way my glucose stats respond to medications, eating and exercising, whether or not I believe the absolute levels are concerning.

Writing inScience Magazinelast year, Charles Piller reviewed the ADA guidelines and found a consensus in the opposite direction that they were probably too strict, and unnecessarily worrisome to a great many people. By ADAs definition, 80 million Americans are pre-diabetic, which is 40% of the adult population. The conflict really is not over the statistics but the interpretation. You can say either People with A1c levels above 6 are at increased risk of progressing to diabetes or equally well, Most people with A1c levels less than 6.4 will never develop diabetes. Both statements are true.

As promised: my experience

The Freestyle Libre was very easy to use and set up. I followed the instructions and used a spring-loaded device to insert the monitor behind my biceps. It was painless. Theres a tiny wire that goes a few millimeters into the skin and an adhesive covering with a button containing the electronics.

The wearable button stores data for up to 8 hours. The other part of the kit is a reader that downloads data every time you bring the reader within an inch or two of the button. As long as you take a reading every 8 hours or less, you wont lose any data. And you can do it as often as you like, to get real time feedback on your glucose state.

The wearable button ($45) is meant to last two weeks, and then it must be discarded. My insurance (Blue Cross Medicare Advantage) wouldnt pay for it because I didnt have a diagnosis of diabetes. I found this out only after several trips to the drug store, interspersed with phone calls to Blue Cross, where I got repeated assurances that it would be covered. The reader ($85) can be reused. Apparently, it doesnt do anything that a cell phone app couldnt do, but Abbott (parent company of Freestyle) has arranged it so that you can only use the cell phone app if you purchase the reader.

To analyze historic data, you can use capabilities built into the phone app, or plug the reader or cell phone into a computer, using a USB cable. The data is uploaded to aweb sitecontaining analysis tools and an option for creating a CSV file for more detailed manipulation in a spreadsheet. (The download button is not so easy to find, but I called Abbotts tech support number, and connected without excessive wait time to a friendly and knowledgeable technician.)

My intention was to vary the glycemic content of my meals, my exercise schedule, eating and fasting schedule, and the medications I was taking (metformin and berberine) to learn what I could about glucose management. The first day I fasted, and I was concerned to see that all day my fasting glucose ranged between 110 and 120. (For reference: the standard healthy range for fasting glucose is 70-100. Below 70 is hypoglycemia. Above 100 is pre-diabetes and above 125 is type 2 diabetes.)

I ate a meal, and glucose shot up to 179 before bedtime, only gradually coming back down during the night. As it turned out, 179 was my high for the week.

The data is cut off after 10 days, though the monitor is supposed to have a lifetime of 14, because it fell off my arm. I looked for patterns in my data, and was able to learn only four things:

(In a long phone support session with an Abbott representative, they acknowledged the reality of my experience: that the monitor can loosen over time, resulting in readings that are anomalously low. They were happy to replace the monitor, and advised me against long periods of swimming. )

Unresolved

I was left wondering all the things I wanted to discover at the beginning of my experiment.

The thing that impressed me most was the natural variability of blood sugar, changing from hour to hour, uncorrelated with either food or exercise. I trust the body knows what its doing. Le corps a ses raisons que la raison ne connait pas.*

I hope to try the monitor for 2 weeks again when swimming season is over.

In the meantime, I am taking a modest, common-sense approach. I am going to leave out metformin but continue daily exercise and low doses of berberine andGynostemma, lightening my evening meal and ending the days food 3 hours before bedtime.

Walking burns calories (pulls sugar from the blood) 3 to 5 times as fast as sitting, and walking after a meal feels like a natural and pleasant thing to do. My doctor recommends it. Im going to try walking half an hour after breakfast and dinner, pending my next experiment with the CGM.

Continue reading here:
What I Learned from the Glucose... - ScienceBlog.com

Recommendation and review posted by Bethany Smith

Emergent BioSolutions highlights the tragedy of tens of thousands of opioid overdose deaths annuallyenough to fill a baseball stadiumby teaming up with several Major League Baseball teams.

The Cut Out Overdoses campaign directs people to a website where they enter a virtual stadium filled with fan silhouettes. Tappingona silhouetteopens up the storyof a person who died of a drug overdose.

Heartbreaking stories written by family members delve into the lives of overdose victims like Jarrod, who was 19 and loved playing baseball with his younger brother, or Tara, who had bright blue eyes and a laugh that helped melt others worries away. Each story ends with the message,Its too late to save them, but its not too late to save someone you love.

Improving Patient Outcomes & Clinical Trials With Visual Analytics

Drug Development has always been about data. Research insight that comes from data often gets muddied by its vastness and inaccessibility. In this session we discuss Takeda Pharmaceuticals Platypus, a comprehensive set of Tableau visualizations of clinical trial data. Register for this webinar to learn more.

RELATED:Emergent's next-gen nasal spray device snares shelf life extension for opioid overdose drug Narcan

The stories also encourage viewers to Take a Stand by talking to doctors or pharmacists about overdose reversal medicine; sharing the hashtag #CutOutOverdose; or donating to the non-profit advocacy group Mothers Against Prescription Drug Abuse (MAPDA).

Three MLB teamsthe Boston Red Sox, Cincinnati Reds and Philadelphia Philliesalong with MAPDA, will highlight the overdose problem at their stadiums with special announcements, videos and presentations. The effort coincides with International OverdoseAwareness Day today.

Emergent bought Adapt Pharma and its flagship product Narcan nasal spray, approved as an emergency treatment of opioid overdose, in a $735 million deal in 2018. Sales of Narcan were $145 million for the first six months of 2020, an increase of 5% over the same time period in 2019.

RELATED:AstraZeneca pledges $174M to ramp up coronavirus vaccine supply deal with Emergent

The campaign website points out that one person dies of an accidental opioid overdose every 15 minutes. Thats almost 47,000 Americans every year, and as the landing page says, Its unacceptable.

Doug White, SVP and devices business unit head at Emergent saidin a news release that the campaign is meant to highlight the important role that overdose reversal medicines play in preparing individuals and families in the event of an accidental opioid overdose.

Read more here:
Emergent steps to the plate with Major League Baseball and virtual experience for opioid overdose awareness - FiercePharma

Recommendation and review posted by Bethany Smith

Milk Thistle Health Tonic Market

Los Angeles, United States,QY Research has published the latest and most trending report on Milk Thistle Health Tonic Marketoffers detailed value chain assessment, a comprehensive study on market dynamics including drivers, restraints and opportunities, recent trends, and industry performance analysis. Furthermore, it digs deep into critical aspects of key subjects such as market competition, regional growth, and market segmentation so that readers could gain a sound understanding of the global Milk Thistle Health Tonic market.

The global Milk Thistle Health Tonic market is valued at million US$ in 2019 is expected to reach million US$ by the end of 2026, growing at a CAGR of during 2020-2026

Get PDF Sample Copy of this Report:https://www.qyresearch.com/sample-form/form/1703248/global-milk-thistle-health-tonic-market

The report represents the statistical data in the form of tables, charts, and info-graphics to assess the market, its growth and development, and market trends of the Global Milk Thistle Health Tonic market during the projected period.

Key Players of the Global Milk Thistle Health Tonic Market

, Health Genesis, Pure Encapsulations, Regis, Solgar, Aksuvital, BEC, NC, Life Extension, Swisse, HerbsofGold

Global Milk Thistle Health Tonic Market: Segmentation by Product

, Tablets, Capsules, Others

Global Milk Thistle Health Tonic Market: Segmentation by Application

Dietary Supplement, Health Food Health Genesis, Pure Encapsulations, Regis, Solgar, Aksuvital, BEC, NC, Life Extension, Swisse, HerbsofGold

In terms of region, this research report covers almost all the major regions across the globe such asNorth America, Europe, South America, the Middle East, and Africa and the Asia Pacific. Europe and North America regions are anticipated to show an upward growth in the years to come. While Milk Thistle Health Tonic Market in Asia Pacific regions is likely to show remarkable growth during the forecasted period. Cutting edge technology and innovations are the most important traits of the North America region and thats the reason most of the time the US dominates the global markets. Milk Thistle Health Tonic Market in South, America region is also expected to grow in near future.

Request Customization of Report:https://www.qyresearch.com/customize-request/form/1703248/global-milk-thistle-health-tonic-market

Table of Contents

1 Milk Thistle Health Tonic Market Overview 1.1 Milk Thistle Health Tonic Product Overview 1.2 Milk Thistle Health Tonic Market Segment by Type1.2.1 Tablets1.2.2 Capsules1.2.3 Others 1.3 Global Milk Thistle Health Tonic Market Size by Type (2015-2026)1.3.1 Global Milk Thistle Health Tonic Market Size Overview by Type (2015-2026)1.3.2 Global Milk Thistle Health Tonic Historic Market Size Review by Type (2015-2020)

1.3.2.1 Global Milk Thistle Health Tonic Sales Market Share Breakdown by Type (2015-2026)

1.3.2.2 Global Milk Thistle Health Tonic Revenue Market Share Breakdown by Type (2015-2026)

1.3.2.3 Global Milk Thistle Health Tonic Average Selling Price (ASP) by Type (2015-2026)1.3.3 Global Milk Thistle Health Tonic Market Size Forecast by Type (2021-2026)

1.3.3.1 Global Milk Thistle Health Tonic Sales Market Share Breakdown by Application (2021-2026)

1.3.3.2 Global Milk Thistle Health Tonic Revenue Market Share Breakdown by Application (2021-2026)

1.3.3.3 Global Milk Thistle Health Tonic Average Selling Price (ASP) by Application (2021-2026) 1.4 Key Regions Market Size Segment by Type (2015-2020)1.4.1 North America Milk Thistle Health Tonic Sales Breakdown by Type (2015-2026)1.4.2 Europe Milk Thistle Health Tonic Sales Breakdown by Type (2015-2026)1.4.3 Asia-Pacific Milk Thistle Health Tonic Sales Breakdown by Type (2015-2026)1.4.4 Latin America Milk Thistle Health Tonic Sales Breakdown by Type (2015-2026)1.4.5 Middle East and Africa Milk Thistle Health Tonic Sales Breakdown by Type (2015-2026) 1.5 Coronavirus Disease 2019 (Covid-19): Milk Thistle Health Tonic Industry Impact1.5.1 How the Covid-19 is Affecting the Milk Thistle Health Tonic Industry

1.5.1.1 Milk Thistle Health Tonic Business Impact Assessment Covid-19

1.5.1.2 Supply Chain Challenges

1.5.1.3 COVID-19s Impact On Crude Oil and Refined Products1.5.2 Market Trends and Milk Thistle Health Tonic Potential Opportunities in the COVID-19 Landscape1.5.3 Measures / Proposal against Covid-19

1.5.3.1 Government Measures to Combat Covid-19 Impact

1.5.3.2 Proposal for Milk Thistle Health Tonic Players to Combat Covid-19 Impact 2 Global Milk Thistle Health Tonic Market Competition by Company 2.1 Global Top Players by Milk Thistle Health Tonic Sales (2015-2020) 2.2 Global Top Players by Milk Thistle Health Tonic Revenue (2015-2020) 2.3 Global Top Players Milk Thistle Health Tonic Average Selling Price (ASP) (2015-2020) 2.4 Global Top Manufacturers Milk Thistle Health Tonic Manufacturing Base Distribution, Sales Area, Product Type 2.5 Milk Thistle Health Tonic Market Competitive Situation and Trends2.5.1 Milk Thistle Health Tonic Market Concentration Rate (2015-2020)2.5.2 Global 5 and 10 Largest Manufacturers by Milk Thistle Health Tonic Sales and Revenue in 2019 2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Milk Thistle Health Tonic as of 2019) 2.7 Date of Key Manufacturers Enter into Milk Thistle Health Tonic Market 2.8 Key Manufacturers Milk Thistle Health Tonic Product Offered 2.9 Mergers & Acquisitions, Expansion 3 Global Milk Thistle Health Tonic Status and Outlook by Region (2015-2026) 3.1 Global Milk Thistle Health Tonic Market Size and CAGR by Region: 2015 VS 2020 VS 2026 3.2 Global Milk Thistle Health Tonic Market Size Market Share by Region (2015-2020)3.2.1 Global Milk Thistle Health Tonic Sales Market Share by Region (2015-2020)3.2.2 Global Milk Thistle Health Tonic Revenue Market Share by Region (2015-2020)3.2.3 Global Milk Thistle Health Tonic Sales, Revenue, Price and Gross Margin (2015-2020) 3.3 Global Milk Thistle Health Tonic Market Size Market Share by Region (2021-2026)3.3.1 Global Milk Thistle Health Tonic Sales Market Share by Region (2021-2026)3.3.2 Global Milk Thistle Health Tonic Revenue Market Share by Region (2021-2026)3.3.3 Global Milk Thistle Health Tonic Sales, Revenue, Price and Gross Margin (2021-2026) 3.4 North America Milk Thistle Health Tonic Market Size YoY Growth (2015-2026)3.4.1 North America Milk Thistle Health Tonic Revenue YoY Growth (2015-2026)3.4.2 North America Milk Thistle Health Tonic Sales YoY Growth (2015-2026) 3.5 Asia-Pacific Milk Thistle Health Tonic Market Size YoY Growth (2015-2026)3.5.1 Asia-Pacific Milk Thistle Health Tonic Revenue YoY Growth (2015-2026)3.5.2 Asia-Pacific Milk Thistle Health Tonic Sales YoY Growth (2015-2026) 3.6 Europe Milk Thistle Health Tonic Market Size YoY Growth (2015-2026)3.6.1 Europe Milk Thistle Health Tonic Revenue YoY Growth (2015-2026)3.6.2 Europe Milk Thistle Health Tonic Sales YoY Growth (2015-2026) 3.7 Latin America Milk Thistle Health Tonic Market Size YoY Growth (2015-2026)3.7.1 Latin America Milk Thistle Health Tonic Revenue YoY Growth (2015-2026)3.7.2 Latin America Milk Thistle Health Tonic Sales YoY Growth (2015-2026) 3.8 Middle East and Africa Milk Thistle Health Tonic Market Size YoY Growth (2015-2026)3.8.1 Middle East and Africa Milk Thistle Health Tonic Revenue YoY Growth (2015-2026)3.8.2 Middle East and Africa Milk Thistle Health Tonic Sales YoY Growth (2015-2026) 4 Global Milk Thistle Health Tonic by Application 4.1 Milk Thistle Health Tonic Segment by Application4.1.1 Dietary Supplement4.1.2 Health Food 4.2 Global Milk Thistle Health Tonic Sales by Application: 2015 VS 2020 VS 2026 4.3 Global Milk Thistle Health Tonic Historic Sales by Application (2015-2020) 4.4 Global Milk Thistle Health Tonic Forecasted Sales by Application (2021-2026) 4.5 Key Regions Milk Thistle Health Tonic Market Size by Application4.5.1 North America Milk Thistle Health Tonic by Application4.5.2 Europe Milk Thistle Health Tonic by Application4.5.3 Asia-Pacific Milk Thistle Health Tonic by Application4.5.4 Latin America Milk Thistle Health Tonic by Application4.5.5 Middle East and Africa Milk Thistle Health Tonic by Application 5 North America Milk Thistle Health Tonic Market Size by Country (2015-2026) 5.1 North America Market Size Market Share by Country (2015-2020)5.1.1 North America Milk Thistle Health Tonic Sales Market Share by Country (2015-2020)5.1.2 North America Milk Thistle Health Tonic Revenue Market Share by Country (2015-2020) 5.2 North America Market Size Market Share by Country (2021-2026)5.2.1 North America Milk Thistle Health Tonic Sales Market Share by Country (2021-2026)5.2.2 North America Milk Thistle Health Tonic Revenue Market Share by Country (2021-2026) 5.3 North America Market Size YoY Growth by Country5.3.1 U.S. Milk Thistle Health Tonic Market Size YoY Growth (2015-2026)5.3.2 Canada Milk Thistle Health Tonic Market Size YoY Growth (2015-2026) 6 Europe Milk Thistle Health Tonic Market Size by Country (2015-2026) 6.1 Europe Market Size Market Share by Country (2015-2020)6.1.1 Europe Milk Thistle Health Tonic Sales Market Share by Country (2015-2020)6.1.2 Europe Milk Thistle Health Tonic Revenue Market Share by Country (2015-2020) 6.2 Europe Market Size Market Share by Country (2021-2026)6.2.1 Europe Milk Thistle Health Tonic Sales Market Share by Country (2021-2026)6.2.2 Europe Milk Thistle Health Tonic Revenue Market Share by Country (2021-2026) 6.3 Europe Market Size YoY Growth by Country6.3.1 Germany Milk Thistle Health Tonic Market Size YoY Growth (2015-2026)6.3.2 France Milk Thistle Health Tonic Market Size YoY Growth (2015-2026)6.3.3 U.K. Milk Thistle Health Tonic Market Size YoY Growth (2015-2026)6.3.4 Italy Milk Thistle Health Tonic Market Size YoY Growth (2015-2026)6.3.5 Russia Milk Thistle Health Tonic Market Size YoY Growth (2015-2026) 7 Asia-Pacific Milk Thistle Health Tonic Market Size by Country (2015-2026) 7.1 Asia-Pacific Market Size Market Share by Country (2015-2020)7.1.1 Asia-Pacific Milk Thistle Health Tonic Sales Market Share by Country (2015-2020)7.1.2 Asia-Pacific Milk Thistle Health Tonic Revenue Market Share by Country (2015-2020) 7.2 Asia-Pacific Market Size Market Share by Country (2021-2026)7.2.1 Asia-Pacific Milk Thistle Health Tonic Sales Market Share by Country (2021-2026)7.2.2 Asia-Pacific Milk Thistle Health Tonic Revenue Market Share by Country (2021-2026) 7.3 Asia-Pacific Market Size YoY Growth by Country7.3.1 China Milk Thistle Health Tonic Market Size YoY Growth (2015-2026)7.3.2 Japan Milk Thistle Health Tonic Market Size YoY Growth (2015-2026)7.3.3 South Korea Milk Thistle Health Tonic Market Size YoY Growth (2015-2026)7.3.4 India Milk Thistle Health Tonic Market Size YoY Growth (2015-2026)7.3.5 Australia Milk Thistle Health Tonic Market Size YoY Growth (2015-2026)7.3.6 Taiwan Milk Thistle Health Tonic Market Size YoY Growth (2015-2026)7.3.7 Indonesia Milk Thistle Health Tonic Market Size YoY Growth (2015-2026)7.3.8 Thailand Milk Thistle Health Tonic Market Size YoY Growth (2015-2026)7.3.9 Malaysia Milk Thistle Health Tonic Market Size YoY Growth (2015-2026)7.3.10 Philippines Milk Thistle Health Tonic Market Size YoY Growth (2015-2026)7.3.11 Vietnam Milk Thistle Health Tonic Market Size YoY Growth (2015-2026) 8 Latin America Milk Thistle Health Tonic Market Size by Country (2015-2026) 8.1 Latin America Market Size Market Share by Country (2015-2020)8.1.1 Latin America Milk Thistle Health Tonic Sales Market Share by Country (2015-2020)8.1.2 Latin America Milk Thistle Health Tonic Revenue Market Share by Country (2015-2020) 8.2 Latin America Market Size Market Share by Country (2021-2026)8.2.1 Latin America Milk Thistle Health Tonic Sales Market Share by Country (2021-2026)8.2.2 Latin America Milk Thistle Health Tonic Revenue Market Share by Country (2021-2026) 8.3 Latin America Market Size YoY Growth by Country8.3.1 Mexico Milk Thistle Health Tonic Market Size YoY Growth (2015-2026)8.3.2 Brazil Milk Thistle Health Tonic Market Size YoY Growth (2015-2026)8.3.3 Argentina Milk Thistle Health Tonic Market Size YoY Growth (2015-2026) 9 Middle East and Africa Milk Thistle Health Tonic Market Size by Country (2015-2026) 9.1 Middle East and Africa Market Size Market Share by Country (2015-2020)9.1.1 Middle East and Africa Milk Thistle Health Tonic Sales Market Share by Country (2015-2020)9.1.2 Middle East and Africa Milk Thistle Health Tonic Revenue Market Share by Country (2015-2020) 9.2 Middle East and Africa Market Size Market Share by Country (2021-2026)9.2.1 Middle East and Africa Milk Thistle Health Tonic Sales Market Share by Country (2021-2026)9.2.2 Middle East and Africa Milk Thistle Health Tonic Revenue Market Share by Country (2021-2026) 9.3 Middle East and Africa Market Size YoY Growth by Country9.3.1 Turkey Milk Thistle Health Tonic Market Size YoY Growth (2015-2026)9.3.2 Saudi Arabia Milk Thistle Health Tonic Market Size YoY Growth (2015-2026)9.3.3 U.A.E Milk Thistle Health Tonic Market Size YoY Growth (2015-2026) 10 Company Profiles and Key Figures in Milk Thistle Health Tonic Business 10.1 Health Genesis10.1.1 Health Genesis Corporation Information10.1.2 Health Genesis Description, Business Overview and Total Revenue10.1.3 Health Genesis Milk Thistle Health Tonic Sales, Revenue and Gross Margin (2015-2020)10.1.4 Health Genesis Milk Thistle Health Tonic Products Offered10.1.5 Health Genesis Recent Development 10.2 Pure Encapsulations10.2.1 Pure Encapsulations Corporation Information10.2.2 Pure Encapsulations Description, Business Overview and Total Revenue10.2.3 Pure Encapsulations Milk Thistle Health Tonic Sales, Revenue and Gross Margin (2015-2020)10.2.4 Health Genesis Milk Thistle Health Tonic Products Offered10.2.5 Pure Encapsulations Recent Development 10.3 Regis10.3.1 Regis Corporation Information10.3.2 Regis Description, Business Overview and Total Revenue10.3.3 Regis Milk Thistle Health Tonic Sales, Revenue and Gross Margin (2015-2020)10.3.4 Regis Milk Thistle Health Tonic Products Offered10.3.5 Regis Recent Development 10.4 Solgar10.4.1 Solgar Corporation Information10.4.2 Solgar Description, Business Overview and Total Revenue10.4.3 Solgar Milk Thistle Health Tonic Sales, Revenue and Gross Margin (2015-2020)10.4.4 Solgar Milk Thistle Health Tonic Products Offered10.4.5 Solgar Recent Development 10.5 Aksuvital10.5.1 Aksuvital Corporation Information10.5.2 Aksuvital Description, Business Overview and Total Revenue10.5.3 Aksuvital Milk Thistle Health Tonic Sales, Revenue and Gross Margin (2015-2020)10.5.4 Aksuvital Milk Thistle Health Tonic Products Offered10.5.5 Aksuvital Recent Development 10.6 BEC10.6.1 BEC Corporation Information10.6.2 BEC Description, Business Overview and Total Revenue10.6.3 BEC Milk Thistle Health Tonic Sales, Revenue and Gross Margin (2015-2020)10.6.4 BEC Milk Thistle Health Tonic Products Offered10.6.5 BEC Recent Development 10.7 NC10.7.1 NC Corporation Information10.7.2 NC Description, Business Overview and Total Revenue10.7.3 NC Milk Thistle Health Tonic Sales, Revenue and Gross Margin (2015-2020)10.7.4 NC Milk Thistle Health Tonic Products Offered10.7.5 NC Recent Development 10.8 Life Extension10.8.1 Life Extension Corporation Information10.8.2 Life Extension Description, Business Overview and Total Revenue10.8.3 Life Extension Milk Thistle Health Tonic Sales, Revenue and Gross Margin (2015-2020)10.8.4 Life Extension Milk Thistle Health Tonic Products Offered10.8.5 Life Extension Recent Development 10.9 Swisse10.9.1 Swisse Corporation Information10.9.2 Swisse Description, Business Overview and Total Revenue10.9.3 Swisse Milk Thistle Health Tonic Sales, Revenue and Gross Margin (2015-2020)10.9.4 Swisse Milk Thistle Health Tonic Products Offered10.9.5 Swisse Recent Development 10.10 HerbsofGold10.10.1 Company Basic Information, Manufacturing Base and Competitors10.10.2 Milk Thistle Health Tonic Product Category, Application and Specification10.10.3 HerbsofGold Milk Thistle Health Tonic Sales, Revenue, Price and Gross Margin (2015-2020)10.10.4 Main Business Overview10.10.5 HerbsofGold Recent Development 11 Milk Thistle Health Tonic Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis 11.1 Milk Thistle Health Tonic Key Raw Materials11.1.1 Key Raw Materials11.1.2 Key Raw Materials Price11.1.3 Raw Materials Key Suppliers11.2 Manufacturing Cost Structure11.2.1 Raw Materials11.2.2 Labor Cost11.2.3 Manufacturing Expenses 11.3 Milk Thistle Health Tonic Industrial Chain Analysis 11.4 Market Opportunities, Challenges, Risks and Influences Factors Analysis11.4.1 Market Opportunities and Drivers11.4.2 Market Challenges11.4.3 Market Risks11.4.4 Porters Five Forces Analysis 12 Market Strategy Analysis, Distributors 12.1 Sales Channel 12.2 Distributors 12.3 Downstream Customers 13 Research Findings and Conclusion 14 Appendix 14.1 Methodology/Research Approach14.1.1 Research Programs/Design14.1.2 Market Size Estimation14.1.3 Market Breakdown and Data Triangulation 14.2 Data Source14.2.1 Secondary Sources14.2.2 Primary Sources 14.3 Author Details 14.4 Disclaimer

About Us:

QYResearchalways pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Go here to read the rest:
Global Milk Thistle Health Tonic Market: Industry Trend Analysis, Revenue, Sales, Competition Tracking, Key Drivers And Forecast Period...

Recommendation and review posted by Bethany Smith

Milk Thistle Health Tonic, Market

LOS ANGELES, United States:QY Research report onMilk Thistle Health Tonic, Market 2020analyzes prospects in the market and presents insights and updates about various segments of the global Milk Thistle Health Tonic, market during the forecast period. The report starts with an executive summary that includes key findings and statistics of the market. It also includes the supply and demand trends governing the global Milk Thistle Health Tonic, market. The report aims to bring to their readers a detailed analysis and the best material to fulfill the requirements of accurate analysis of the global Milk Thistle Health Tonic, market. The report is completed with all aspects, as it covers all key components with industry experts opinions and valuable statistics in all regards.

Scope of the Global Milk Thistle Health Tonic, Market

The global Milk Thistle Health Tonic, market report covers an overall scope and product overview to define the key terms and offers the clients a general idea of the market and its trends. This is followed by the regional outlook and segmentation of the market. The report also contains facts and key values of the global Milk Thistle Health Tonic, market in terms of sales and its growth rate, sales and volume, and revenue and its growth rate.

The report also discusses the breakdown of data over different parameters to arrive at the market numbers. Besides, the competitive landscape of the global Milk Thistle Health Tonic, market has also been covered in this report by providing information about leading players in the market. The report follows an exclusive market strategy, PESTEL analysis, and SWOT analysis for the players operating in the global Milk Thistle Health Tonic, market.

Global Milk Thistle Health Tonic, market: Competitive Landscape

The competitive dashboard provides a detailed comparison of Milk Thistle Health Tonic, manufacturers on valuable parameters such as key developments, key strategies, total revenue, and key product offerings. In-depth profiles of top players are included in the report to analyze their significant role in the global Milk Thistle Health Tonic, market.

Request for a sample copy of this report:https://www.qyresearch.com/sample-form/form/1702900/impact-of-covid-19-outbreak-on-milk-thistle-health-tonic-global-market

The major players that are operating in the global Milk Thistle Health Tonic, market are:

Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 200 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Milk Thistle Health Tonic market in 2020. COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future. This report also analyses the impact of Coronavirus COVID-19 on the Milk Thistle Health Tonic industry. Prior to COVID-19, the global market for Milk Thistle Health Tonic was anticipated to grow from US$ XX million in 2020 to US$ XX million by 2026; it is expected to grow at a CAGR of xx% during 20212026, whereas post-COVID-19 scenario, the market for Milk Thistle Health Tonic is projected to grow from US$ XX million in 2020 (a change by ~XX% compared to market estimated for 2020 before the outbreak of COVID-19) to US$ XX billion by 2026; it is expected to grow at a CAGR of XX% during 20212026. QY Research has recently curated a research report titled, Global Milk Thistle Health Tonic Market Research Report 2020. The report is structured on primary and secondary research methodologies that derive historic and forecast data. The global Milk Thistle Health Tonic market is growing remarkably fast and is likely to thrive in terms of volume and revenue during the forecast period. Readers can gain insight into the various opportunities and restraints shaping the market. The report demonstrates the progress and bends that will occur during the forecast period. Global Milk Thistle Health Tonic Market: Drivers and Restrains The research report has incorporated the analysis of different factors that augment the markets growth. It constitutes trends, restraints, and drivers that transform the market in either a positive or negative manner. This section also provides the scope of different segments and applications that can potentially influence the market in the future. The detailed information is based on current trends and historic milestones. This section also provides an analysis of the volume of sales about the global market and also about each type from 2015 to 2026. This section mentions the volume of sales by region from 2015 to 2026. Pricing analysis is included in the report according to each type from the year 2015 to 2026, manufacturer from 2015 to 2020, region from 2015 to 2020, and global price from 2015 to 2026. A thorough evaluation of the restrains included in the report portrays the contrast to drivers and gives room for strategic planning. Factors that overshadow the market growth are pivotal as they can be understood to devise different bends for getting hold of the lucrative opportunities that are present in the ever-growing market. Additionally, insights into market experts opinions have been taken to understand the market better. Global Milk Thistle Health Tonic Market: Segment Analysis The research report includes specific segments such as application and product type. Each type provides information about the sales during the forecast period of 2015 to 2026. The application segment also provides revenue by volume and sales during the forecast period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Global Milk Thistle Health Tonic Market: Regional Analysis The research report includes a detailed study of regions of North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region. Analysts have studied the data of revenue, sales, and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2015 to 2026. These analyses will help the reader to understand the potential worth of investment in a particular region. Global Milk Thistle Health Tonic Market: Competitive Landscape This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019. Following are the segments covered by the report are:, Tablets, Capsules, Others By Application:, Dietary Supplement, Health Food Key Players: The Key manufacturers that are operating in the global Milk Thistle Health Tonic market are:, Health Genesis, Pure Encapsulations, Regis, Solgar, Aksuvital, BEC, NC, Life Extension, Swisse, HerbsofGold Competitive Landscape The analysts have provided a comprehensive analysis of the competitive landscape of the global Milk Thistle Health Tonic market with the company market structure and market share analysis of the top players. The innovative trends and developments, mergers and acquisitions, product portfolio, and new product innovation to provide a dashboard view of the market, ultimately providing the readers accurate measure of the current market developments, business strategies, and key financials.

Global Milk Thistle Health Tonic, market: Regional Analysis

This section of the report highlights the region-wise analysis of the global Milk Thistle Health Tonic, market. The report is mainly segmented into key geographical regions such as Europe, the Middle East and Africa, North America, South America, and Asia Pacific. The report also provides an in-depth analysis of the pricing analysis, market growth, and regional trends across various regions of the global Milk Thistle Health Tonic, market.

Global Milk Thistle Health Tonic, market: Forecast by Segments

The global Milk Thistle Health Tonic, market is segmented into different sections such as product and end user. For the better understanding of the report, our expert team of research analysts have noted down the relative contribution of each segment for the development of the global Milk Thistle Health Tonic, market. Detailed information of the segments is required to find out the key trends and developments that are influencing the Milk Thistle Health Tonic, market.

Global Milk Thistle Health Tonic, Market by Product Type:

Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 200 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Milk Thistle Health Tonic market in 2020. COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future. This report also analyses the impact of Coronavirus COVID-19 on the Milk Thistle Health Tonic industry. Prior to COVID-19, the global market for Milk Thistle Health Tonic was anticipated to grow from US$ XX million in 2020 to US$ XX million by 2026; it is expected to grow at a CAGR of xx% during 20212026, whereas post-COVID-19 scenario, the market for Milk Thistle Health Tonic is projected to grow from US$ XX million in 2020 (a change by ~XX% compared to market estimated for 2020 before the outbreak of COVID-19) to US$ XX billion by 2026; it is expected to grow at a CAGR of XX% during 20212026. QY Research has recently curated a research report titled, Global Milk Thistle Health Tonic Market Research Report 2020. The report is structured on primary and secondary research methodologies that derive historic and forecast data. The global Milk Thistle Health Tonic market is growing remarkably fast and is likely to thrive in terms of volume and revenue during the forecast period. Readers can gain insight into the various opportunities and restraints shaping the market. The report demonstrates the progress and bends that will occur during the forecast period. Global Milk Thistle Health Tonic Market: Drivers and Restrains The research report has incorporated the analysis of different factors that augment the markets growth. It constitutes trends, restraints, and drivers that transform the market in either a positive or negative manner. This section also provides the scope of different segments and applications that can potentially influence the market in the future. The detailed information is based on current trends and historic milestones. This section also provides an analysis of the volume of sales about the global market and also about each type from 2015 to 2026. This section mentions the volume of sales by region from 2015 to 2026. Pricing analysis is included in the report according to each type from the year 2015 to 2026, manufacturer from 2015 to 2020, region from 2015 to 2020, and global price from 2015 to 2026. A thorough evaluation of the restrains included in the report portrays the contrast to drivers and gives room for strategic planning. Factors that overshadow the market growth are pivotal as they can be understood to devise different bends for getting hold of the lucrative opportunities that are present in the ever-growing market. Additionally, insights into market experts opinions have been taken to understand the market better. Global Milk Thistle Health Tonic Market: Segment Analysis The research report includes specific segments such as application and product type. Each type provides information about the sales during the forecast period of 2015 to 2026. The application segment also provides revenue by volume and sales during the forecast period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Global Milk Thistle Health Tonic Market: Regional Analysis The research report includes a detailed study of regions of North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region. Analysts have studied the data of revenue, sales, and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2015 to 2026. These analyses will help the reader to understand the potential worth of investment in a particular region. Global Milk Thistle Health Tonic Market: Competitive Landscape This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019. Following are the segments covered by the report are:, Tablets, Capsules, Others By Application:, Dietary Supplement, Health Food Key Players: The Key manufacturers that are operating in the global Milk Thistle Health Tonic market are:, Health Genesis, Pure Encapsulations, Regis, Solgar, Aksuvital, BEC, NC, Life Extension, Swisse, HerbsofGold Competitive Landscape The analysts have provided a comprehensive analysis of the competitive landscape of the global Milk Thistle Health Tonic market with the company market structure and market share analysis of the top players. The innovative trends and developments, mergers and acquisitions, product portfolio, and new product innovation to provide a dashboard view of the market, ultimately providing the readers accurate measure of the current market developments, business strategies, and key financials.

Global Milk Thistle Health Tonic, Market by Application:

Dietary Supplement, Health Food Key Players: The Key manufacturers that are operating in the global Milk Thistle Health Tonic market are:, Health Genesis, Pure Encapsulations, Regis, Solgar, Aksuvital, BEC, NC, Life Extension, Swisse, HerbsofGold Competitive Landscape The analysts have provided a comprehensive analysis of the competitive landscape of the global Milk Thistle Health Tonic market with the company market structure and market share analysis of the top players. The innovative trends and developments, mergers and acquisitions, product portfolio, and new product innovation to provide a dashboard view of the market, ultimately providing the readers accurate measure of the current market developments, business strategies, and key financials.

Global Milk Thistle Health Tonic, market: Research Methodology

The report also represents the statistical data in the form of tables, charts, and infographics to predict the market development, growth, trends, and estimates of the global Milk Thistle Health Tonic, market during the assessment period. The analysts have used a framework such as opinions of key industry experts by taking personal interviews, refer journals, research papers and survey papers to know the detailed outlook of the global Milk Thistle Health Tonic, market. The report also consists of the nautical information where it shows Milk Thistle Health Tonic, market product volume, manufacturing process, and utilization value.

Request Customization of Report :https://www.qyresearch.com/customize-request/form/1702900/impact-of-covid-19-outbreak-on-milk-thistle-health-tonic-global-market

Table of Contents

1 Milk Thistle Health Tonic Market Overview 1.1 Product Overview and Scope of Milk Thistle Health Tonic 1.2 Covid-19 Implications on Milk Thistle Health Tonic Segment by Type1.2.1 Global Milk Thistle Health Tonic Sales Growth Rate Comparison by Type (2021-2026)1.2.2 Tablets1.2.3 Capsules1.2.4 Others 1.3 Covid-19 Implications on Milk Thistle Health Tonic Segment by Application1.3.1 Milk Thistle Health Tonic Sales Comparison by Application: 2020 VS 20261.3.2 Dietary Supplement1.3.3 Health Food 1.4 Covid-19 Implications on Global Milk Thistle Health Tonic Market Size Estimates and Forecasts1.4.1 Global Milk Thistle Health Tonic Revenue 2015-20261.4.2 Global Milk Thistle Health Tonic Sales 2015-20261.4.3 Milk Thistle Health Tonic Market Size by Region: 2020 Versus 2026 1.5 Coronavirus Disease 2019 (Covid-19): Milk Thistle Health Tonic Industry Impact1.5.1 How the Covid-19 is Affecting the Milk Thistle Health Tonic Industry

1.5.1.1 Milk Thistle Health Tonic Business Impact Assessment Covid-19

1.5.1.2 Supply Chain Challenges

1.5.1.3 COVID-19s Impact On Crude Oil and Refined Products1.5.2 Market Trends and Milk Thistle Health Tonic Potential Opportunities in the COVID-19 Landscape1.5.3 Measures / Proposal against Covid-19

1.5.3.1 Government Measures to Combat Covid-19 Impact

1.5.3.2 Proposal for Milk Thistle Health Tonic Players to Combat Covid-19 Impact 2 Covid-19 Implications on Global Milk Thistle Health Tonic Market Competition by Manufacturers 2.1 Global Milk Thistle Health Tonic Sales Market Share by Manufacturers (2015-2020) 2.2 Global Milk Thistle Health Tonic Revenue Share by Manufacturers (2015-2020) 2.3 Global Milk Thistle Health Tonic Average Price by Manufacturers (2015-2020) 2.4 Manufacturers Milk Thistle Health Tonic Manufacturing Sites, Area Served, Product Type 2.5 Milk Thistle Health Tonic Market Competitive Situation and Trends2.5.1 Milk Thistle Health Tonic Market Concentration Rate2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans 2.7 Primary Interviews with Key Milk Thistle Health Tonic Players (Opinion Leaders) 3 Covid-19 Implications on Milk Thistle Health Tonic Retrospective Market Scenario by Region 3.1 Global Milk Thistle Health Tonic Retrospective Market Scenario in Sales by Region: 2015-2020 3.2 Global Milk Thistle Health Tonic Retrospective Market Scenario in Revenue by Region: 2015-2020 3.3 North America Milk Thistle Health Tonic Market Facts & Figures by Country3.3.1 North America Milk Thistle Health Tonic Sales by Country3.3.2 North America Milk Thistle Health Tonic Sales by Country3.3.3 U.S.3.3.4 Canada 3.4 Europe Milk Thistle Health Tonic Market Facts & Figures by Country3.4.1 Europe Milk Thistle Health Tonic Sales by Country3.4.2 Europe Milk Thistle Health Tonic Sales by Country3.4.3 Germany3.4.4 France3.4.5 U.K.3.4.6 Italy3.4.7 Russia 3.5 Asia Pacific Milk Thistle Health Tonic Market Facts & Figures by Region3.5.1 Asia Pacific Milk Thistle Health Tonic Sales by Region3.5.2 Asia Pacific Milk Thistle Health Tonic Sales by Region3.5.3 China3.5.4 Japan3.5.5 South Korea3.5.6 India3.5.7 Australia3.5.8 Taiwan3.5.9 Indonesia3.5.10 Thailand3.5.11 Malaysia3.5.12 Philippines3.5.13 Vietnam 3.6 Latin America Milk Thistle Health Tonic Market Facts & Figures by Country3.6.1 Latin America Milk Thistle Health Tonic Sales by Country3.6.2 Latin America Milk Thistle Health Tonic Sales by Country3.6.3 Mexico3.6.3 Brazil3.6.3 Argentina 3.7 Middle East and Africa Milk Thistle Health Tonic Market Facts & Figures by Country3.7.1 Middle East and Africa Milk Thistle Health Tonic Sales by Country3.7.2 Middle East and Africa Milk Thistle Health Tonic Sales by Country3.7.3 Turkey3.7.4 Saudi Arabia3.7.5 U.A.E 4 Global Milk Thistle Health Tonic Historic Market Analysis by Type 4.1 Global Milk Thistle Health Tonic Sales Market Share by Type (2015-2020) 4.2 Global Milk Thistle Health Tonic Revenue Market Share by Type (2015-2020) 4.3 Global Milk Thistle Health Tonic Price Market Share by Type (2015-2020) 4.4 Global Milk Thistle Health Tonic Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Global Milk Thistle Health Tonic Historic Market Analysis by Application 5.1 Global Milk Thistle Health Tonic Sales Market Share by Application (2015-2020) 5.2 Global Milk Thistle Health Tonic Revenue Market Share by Application (2015-2020) 5.3 Global Milk Thistle Health Tonic Price by Application (2015-2020) 6 Company Profiles and Key Figures in Milk Thistle Health Tonic Business 6.1 Health Genesis6.1.1 Corporation Information6.1.2 Health Genesis Description, Business Overview and Total Revenue6.1.3 Health Genesis Milk Thistle Health Tonic Sales, Revenue and Gross Margin (2015-2020)6.1.4 Health Genesis Products Offered6.1.5 Health Genesis Recent Development 6.2 Pure Encapsulations6.2.1 Pure Encapsulations Corporation Information6.2.2 Pure Encapsulations Description, Business Overview and Total Revenue6.2.3 Pure Encapsulations Milk Thistle Health Tonic Sales, Revenue and Gross Margin (2015-2020)6.2.4 Pure Encapsulations Products Offered6.2.5 Pure Encapsulations Recent Development 6.3 Regis6.3.1 Regis Corporation Information6.3.2 Regis Description, Business Overview and Total Revenue6.3.3 Regis Milk Thistle Health Tonic Sales, Revenue and Gross Margin (2015-2020)6.3.4 Regis Products Offered6.3.5 Regis Recent Development 6.4 Solgar6.4.1 Solgar Corporation Information6.4.2 Solgar Description, Business Overview and Total Revenue6.4.3 Solgar Milk Thistle Health Tonic Sales, Revenue and Gross Margin (2015-2020)6.4.4 Solgar Products Offered6.4.5 Solgar Recent Development 6.5 Aksuvital6.5.1 Aksuvital Corporation Information6.5.2 Aksuvital Description, Business Overview and Total Revenue6.5.3 Aksuvital Milk Thistle Health Tonic Sales, Revenue and Gross Margin (2015-2020)6.5.4 Aksuvital Products Offered6.5.5 Aksuvital Recent Development 6.6 BEC6.6.1 BEC Corporation Information6.6.2 BEC Description, Business Overview and Total Revenue6.6.3 BEC Milk Thistle Health Tonic Sales, Revenue and Gross Margin (2015-2020)6.6.4 BEC Products Offered6.6.5 BEC Recent Development 6.7 NC6.6.1 NC Corporation Information6.6.2 NC Description, Business Overview and Total Revenue6.6.3 NC Milk Thistle Health Tonic Sales, Revenue and Gross Margin (2015-2020)6.4.4 NC Products Offered6.7.5 NC Recent Development 6.8 Life Extension6.8.1 Life Extension Corporation Information6.8.2 Life Extension Description, Business Overview and Total Revenue6.8.3 Life Extension Milk Thistle Health Tonic Sales, Revenue and Gross Margin (2015-2020)6.8.4 Life Extension Products Offered6.8.5 Life Extension Recent Development 6.9 Swisse6.9.1 Swisse Corporation Information6.9.2 Swisse Description, Business Overview and Total Revenue6.9.3 Swisse Milk Thistle Health Tonic Sales, Revenue and Gross Margin (2015-2020)6.9.4 Swisse Products Offered6.9.5 Swisse Recent Development 6.10 HerbsofGold6.10.1 HerbsofGold Corporation Information6.10.2 HerbsofGold Description, Business Overview and Total Revenue6.10.3 HerbsofGold Milk Thistle Health Tonic Sales, Revenue and Gross Margin (2015-2020)6.10.4 HerbsofGold Products Offered6.10.5 HerbsofGold Recent Development 7 Milk Thistle Health Tonic Manufacturing Cost Analysis 7.1 Milk Thistle Health Tonic Key Raw Materials Analysis7.1.1 Key Raw Materials7.1.2 Key Raw Materials Price Trend7.1.3 Key Suppliers of Raw Materials 7.2 Proportion of Manufacturing Cost Structure 7.3 Manufacturing Process Analysis of Milk Thistle Health Tonic 7.4 Milk Thistle Health Tonic Industrial Chain Analysis 8 Marketing Channel, Distributors and Customers 8.1 Marketing Channel 8.2 Milk Thistle Health Tonic Distributors List 8.3 Milk Thistle Health Tonic Customers 9 Market Dynamics 9.1 Market Trends 9.2 Opportunities and Drivers 9.3 Challenges 9.4 Porters Five Forces Analysis 10 Global Market Forecast 10.1 Global Milk Thistle Health Tonic Market Estimates and Projections by Type10.1.1 Global Forecasted Sales of Milk Thistle Health Tonic by Type (2021-2026)10.1.2 Global Forecasted Revenue of Milk Thistle Health Tonic by Type (2021-2026) 10.2 Milk Thistle Health Tonic Market Estimates and Projections by Application10.2.1 Global Forecasted Sales of Milk Thistle Health Tonic by Application (2021-2026)10.2.2 Global Forecasted Revenue of Milk Thistle Health Tonic by Application (2021-2026) 10.3 Milk Thistle Health Tonic Market Estimates and Projections by Region10.3.1 Global Forecasted Sales of Milk Thistle Health Tonic by Region (2021-2026)10.3.2 Global Forecasted Revenue of Milk Thistle Health Tonic by Region (2021-2026) 10.4 North America Milk Thistle Health Tonic Estimates and Projections (2021-2026) 10.5 Europe Milk Thistle Health Tonic Estimates and Projections (2021-2026) 10.6 Asia Pacific Milk Thistle Health Tonic Estimates and Projections (2021-2026) 10.7 Latin America Milk Thistle Health Tonic Estimates and Projections (2021-2026) 10.8 Middle East and Africa Milk Thistle Health Tonic Estimates and Projections (2021-2026) 11 Research Finding and Conclusion 12 Methodology and Data Source 12.1 Methodology/Research Approach 12.1.1 Research Programs/Design 12.1.2 Market Size Estimation 12.1.3 Market Breakdown and Data Triangulation 12.2 Data Source 12.2.1 Secondary Sources 12.2.2 Primary Sources 12.3 Author List 12.4 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Excerpt from:
Global Market Study On Milk Thistle Health Tonic, : Cutting-Edge Technology Is Anticipated To Boost The Revenue Over The Forecast Period...

Recommendation and review posted by Bethany Smith

Science has evolved significantly over the past century, characterized by a number of innovations specifically in the medical field. One of the groundbreaking and skeptical techniques to ever be invented is that of Cryonics, the low-temperature freezing and storage of a human corpse with the speculative hope that they can be resurrected and restored back to full health in the possible future. A subject that has been regarded with skepticism within the mainstream scientific community, there has been little to no visual documentation of this process until now.

Adding to its ever-growing library of poignant and impactful documentaries, Netflix is set to premiere an incredible moving unscripted film entitled 'Hope Frozen: A Quest to Live Twice' that touches upon Cryonics. It is the story of a Thai Buddhist family and their unorthodox decision to have their two-year-old daughter cryogenically frozen after she died from brain cancer. Here's all you need to know about the film.

'Hope Frozen: A Quest to Live Twice' will be available on Netflix starting September 15.

The documentary chronicles the heart-wrenching journey of Thai Buddhist parents, who make an unconventional decision after the death of their baby daughter. Einz, a two-year-old toddler passed away in January 2015 in Bangkok, Thailand, after battling brain cancer. Her parents had her body cryonically frozen in the hope that she can one day be revived and will fulfill her life in a new body.

Einz became the youngest person in the world to undergo this preservation procedure. Her remains are stored in an American lab, while her head and brain rest inside a tank in Arizona. The 79-minute documentary follows the family who made this unorthodox decision and includes a montage of the family's archival footage.

Einz's father, a laser scientist, yearns to give his deceased daughter the opportunity to experience a rebirth inside a regenerated body, He instills this dream within his son, a precocious 15-year-old named Matrix who also wants to play a role in the revival of his little sister. But what the boy later discovers will rattle the family's radical hope in science.

"It's been an emotional journey to cover Einzs family on their biggest decision and dedication for their daughter. Witnessing the pivotal moments that the family went through was a privilege and a mind-expanding experience. Their story has led me to ask fundamental questions about life, faith, and love. It has touched me in so many ways. I'm so thrilled to share this experience with worldwide viewers on Netflix," said Pailin Wedel, the director and producer of 'Hope Frozen: A Quest to Live Twice'.

"We are delighted to welcome 'Hope Frozen' to our growing slate of award-winning documentaries on Netflix. What makes this announcement extra special, is that the story comes from Thailand, and authentically crafted by Pailin and her team of talented Thai producers. We fully support Pailins vision with the creative freedom to express this unique story of unconditional love, which resonates universally," Adam Del Deo, Vice President of Original Documentary Features said in an official press statement.

The Netflix edition of 'Hope Frozen: A Quest to Live Twice' will be available in 31 languages including dubbing in Brazilian Portuguese, English, French, German, Italian, Latin Spanish, Polish, Spanish (Castilian), Thai and Turkish.

'Hope Frozen: A Quest to Live Twice' is directed by journalist-filmmaker Pailin Wedel who followed the story of the family for the documentary. The film has been recognized with numerous international awards, including the Best International Feature Documentary at Hot Docs Canadian International Documentary Festival 2019. At San Antonio Independent Film Festival 2020, Pailin won Best Documentary Feature for her documentary from more than 900 films that were presented.

'Unrest'

'The Doctor Who Refused to Give Up'

'Code Black'

'The Bleeding Edge'

'The Waiting Room'

Go here to see the original:
'Hope Frozen: A Quest to Live Twice': Release date, plot, trailer and all you need to know about the Netflix d - MEAWW

Recommendation and review posted by Bethany Smith

MarketQuest.bizhas released a new report titledGlobal Cryonics Technology Market 2020 by Company, Type and Application, Forecast to 2025which includes knowledgeable information on industry analysis collected by the leading industry experts and dedicated research analyst team. The researchers team has analyzed the current state of the globalCryonics Technologymarket that covers in-depth market insights such as market definitions, classifications, product specifications, manufacturing processes, cost structures, market segmentation, end-use applications, and market forecast time from 2020 to 2025. The report provides a competitive advantage to clients through a detailed report. The study sheds light on current market trends, opportunities, challenges, and detailed competitive analysis of the industry players in the market.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

DOWNLOAD FREE SAMPLE REPORT:https://www.marketquest.biz/sample-request/2337

Market Description:

The report has congregated a massive amount of data on the key segments of the market in an easy to understand format. The report has included interviews of various delegates of the industry as well as the primary and secondary research to confer the clients with information and strategies to fight against the market challenges. Graphs, tables, charts are added to help have an accurate understanding of this market. It also provides growth rates of key producers operating in the globalCryonics Technologymarket. Furthermore, it offers production and capacity analysis where marketing pricing trends, capacity, production, and production value of the global market are included.

The report presents the market competitive landscape and a corresponding detailed analysis of the major vendor/key players in the market. Top companies in the globalCryonics Technologymarket:Praxair, Custom Biogenic Systems, Cryotherm, Cellulis, Thermo Fisher Scientific, Cryologics, Alcor Life Extension Foundation, VWR, KrioRus, Oregon Cryonics, Osiris Cryonics, Sigma-Aldrich, Southern Cryonics

For a comprehensive understanding of market dynamics, the global market is analyzed across key geographies namely:North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina), Middle East & Africa (Saudi Arabia, UAE, Egypt and South Africa).

ACCESS FULL REPORT:https://www.marketquest.biz/report/2337/global-cryonics-technology-market-2020-by-company-type-and-application-forecast-to-2025

Some of The Key Questions Answered In This Report:

GlobalCryonics Technologymarket report categorizes the global market by key players, product types, applications, and regions. The report pictures in-depth and accurate figures of sales revenue, consumption volume, import/export details, supply/demand chain, technological developments and innovations, profit margin, and gross margin. The report lists out names of major suppliers of product, distributors, dealers, raw material suppliers, end-users, and manufacturers.

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

MarketQuest.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. MarketQuest.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for worlds leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. MarketQuest.biz is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact UsMark StoneHead of Business DevelopmentPhone:+1-201-465-4211Email:[emailprotected]Web:www.marketquest.biz

Read the original:
Global Cryonics Technology Market 2020 with Covid-19 Impact Analysis and Forecast by 2025 - Galus Australis

Recommendation and review posted by Bethany Smith

Warren Buffett turns 90 tomorrow.

The number itself isnt that remarkable (there are a couple million of 90-somethings in the U.S these days). Its what Buffett has accomplishedand what he may still do thats astonishing.

At 90 years of age Buffett has never been more of a force (more on that in a bit). And with all due apologies to his partner, Charlie Munger, nevermind Tony Bennett and Jimmy Carter, Buffett has to be the most impactful nonagenarian in America, if not the world.

Buffetts life and achievements have been singular, and as he never fails to point out, uniquely American. To be clear though, his is not an up-from-poverty story. Buffett came from privilege. His father was a Congressman from Nebraska (and as a die-hard conservative, close to a political opposite of his son.) Still the Buffetts werent rich and beyond that, while his background surely helped, it certainly didnt make him one of the successful people on the planet.

People always ask me what Warren Buffett is like. Well, for one thing hes purposeful and self-aware. Buffett has thought a great deal about longevity, for instance, but not in an obsessive, cryonics way. He told me this in a conversation I had with him last year:

If I gave you a car, and it'd be the only car you get the rest of your life, you'd take care of it like you can't believe. Any scratch, you'd fix that moment. You'd read the owner's manual, and you'd keep a garage, and do all these things. And you get exactly one mind and one body in this world. And you can't start taking care of it when you're 50. By that time, you'll rust it out, if you haven't done anything. So you should really make sure that you just remember that you've just got one mind and body to get through life with, and to do the most with it.

Before I get to his other salient attributes I want to add some disclaimers here because already I can see the Twitterati rolling their eyes, so here goes: Yes, Warren Buffett is a businessman. You may not like some of the companies he owns or in which he has invested. Yes, he makes money, lots of money. (You may not like that either.) Here is a guy who has become extraordinarily wealthy and did it in a fair way, says Robert Miles, longtime Berkshire Hathaway shareholder and author of "The Warren Buffett CEO. But Miles notes: Hes a shark. Obviously youre not going to be that successful and rich without being an ace negotiator.

Story continues

Buffett has made mistakes too, many of them in fact, (which hes happy to discuss.) Also Buffett isnt posing as some sort of country hayseed like some suggest, trying to fool people. Hes actually one of the most sophisticated people youll ever meet. He just happens to be polite, friendly and live in Nebraska. (Do all rich people have to be rude, icy and live in Greenwich?)

His commercial achievements are stunning, which as of today are marked by a pair of sixes. Berkshire Hathaway, which hes run for 55 years, is now the 6th largest company in America, and Buffetts $82 billion fortune makes him the 6th richest citizen of planet Earth. Howd he do that? Its this notion of patience, the notion of focus, and the notion of looking at companies with a telescope is what I think is important to underscore what Buffett is doing, legendary investor Mario Gabelli told me this week. Take the cash up. Let other people run it. Reallocate the cash flow. That's his business skill set. At 90, you don't need hand-eye coordination. So he can do this for another 50 years. I just hope they come up with some medicine, some aphrodisiac or some dynamic that keeps him going.

Buffetts footprint is bigger than ever. He gets even more calls from CEOs, politicians and societal leaders. His market moves attract more attentionlike when he sold airlines stocks or bought gold this year. Internationally hes more well known than hes ever been. Since the financial crisis of 08-09, the luster of the U.S. financial model began to wane in China and all over the world, says Li Lu, founder and chairman of Himalaya Capital Management, a multi-billion dollar investment firm which has business ties to Berkshire Hathaway. The example of Buffett and Berkshire on the contrary have increased their influence precisely because they point to a different way of conducting yourself. Hes singled out as someone whos not typical of American ways. I dont think the current tense relationship between China and the U.S. has in any way dented his reputation.

At 90 years old, thats impact.

But even more than that, Buffett has become a paradigm for living. Thats really why millions around the globe hang on his every word. Or why when you go to his annual meeting in Omaha, tens of thousands sit in stone silence for hours listening to him and Munger wax poetic. Ive always felt it was like a church in there, or a cult, which it kind of is. Except in this cult the members invest in Berkshire Hathaway stock and make moneyand they get to keep it!

Every person Ive ever spoken to about Buffett for any period of time, talks about his effect on them.

Hes made remarkable changes in my life and me personally, says Sharon Osberg, a longtime friend who plays bridge with Buffett a couple times a week. Having the privilege of observing his behavior in difficult situations has taught me a lot about how to do that. And I learned how to be happy. (Osberg recalls that when she first met Buffett decades ago I got into his office, and started rolling dice on the floor. I was on hands and knees rolling dice with him.)

Li Lu says he walked into a lecture Buffett was giving years ago at Columbia University and ...was instantaneously taken by him. What he basically taught me in that course was that somebody with high moral principles and integrity can make a lot of money off the market by being wise and smart and moral, Lu says. For many years, he and Charlie were my role models. Normally I dont take a living person as a role model, knowing how fragile human beings are. But for 25, 30 years he and Charlie never disappointed me in how to conduct business and life.

Says author Miles: Hes transformed my life personally, more than anyone else in terms of modeling good behavior and having fun. Hes made me a better person, made me rethink my own philanthropy, in terms of helping those who through no fault of their own were born on the wrong side of track.

I showed up at the Berkshire meeting to learn how to become rich and make a lot of money and compound stocks at a high rate, says Wall Street hedge fund manager Whitney Tilson. And instead, what I got was a dose of what they call worldly wisdom, about developing good habits and the importance of integrity becoming a learning machine and how to be a good spouse and all these other things that have really helped shape me second only to my parents, I suppose.

Buffett often talks about the importance of giving to your family and friends, the people you love. And he walks this talk, like when he flew to New York in June of last year to attend a 90th birthday party of his long standing pal, Carol Loomis, retired editor at Fortune, and sing a goofy song in her honor. (Now thats how to stay young.)

And theres a zillion more.

I know thats a lot of gushing testimonials. But could anyone really say the same things about Buffetts fellow mega-billionaires Bezos, Zuckerberg, Koch or Bloomberg? True, you might admire them or learn from them, but what people around the globe have received from Buffett is in another league.

Of course everyone always asks what will happen to Berkshire once Buffett finally does retire or pass on. Buffett has heard this 90 million times, and for decades. And hes been working on succession, and for decades. As my colleague Sam Ro points out, its almost as if Buffett wants us to focus on his succession plan because it draws more attention to Berkshire, something Buffett has been unapologetically P.T. Barnumesque about.

And whos to say the torch cant be passed smoothly? Steve Jobs certainly did right by Apple when he picked Tim Cook, a point not lost on Buffett, particularly now that he owns $120 billion of Apple stock, worth almost 25% of Berkshires market value. Buffetts two trusted lieutenants, (Ajit) Jain and (Greg) Abelnot to be confused with Cain and Abel, or at least Berkshire shareholders hope notare increasingly hands on and poised to lead.

When you love your life, of course you want it to go on and on, says Laura Rittenhouse, consultant and author of Buffett's Bites: The Essential Investor's Guide to Warren Buffett's Shareholder Letters. But the fact that he put the succession plan into place says he has certainly confronted the inevitable.

For now and the foreseeable future (whatever that means when youre 90), Buffett is still running things, aware that hes being scrutinized in a way, well, that any 90-year-old CEO would. In fact, Osberg says she and Buffett were just talking about that.

We had that discussion a couple nights ago. He finds it interesting that so many people are interested in his mental faculties. He totally understands, she says. I literally told him this on Tuesday, I have not noticed a decline in him. Hes slower at some things, physically the body gets slower when youre older. He walks slower, knees hurt, or whatever. He would tell you certain things he feels hes slower at mentally, but nothing important. Like remembering names, something that none of us can do anymore. It really is amazing.

A recent interview in a nice piece by the Omaha World Herald this week, noted longevity is in Buffetts familys genes. His mother lived to be 92, and his sister Doris who died this month was also 92. Baby sister Bertie, whom Buffett said he will be visiting next month, is 86. My dad is going to outlive us all, and Im not kidding, said his daughter Susie Buffett in the article. Ill bet a lot of money he will get to 100. (If Buffett did, hed be bucking the odds of course.)

And famously Buffett eats like a first-grader, which he explained to me a couple of years ago: I actually eat exactly what I like to eat. If I liked it on my sixth birthdayon my sixth birthday party, when we had hot dogs, and hamburgers, and Coke, and ice cream with chocolateI still like it. And I don't care about anything, subsequently. I discovered it all by the time I was six. And if somebody offered me a deal when I was 20, and said, you're going to live one year longerinstead of living to 88, you'll live to 89, or whatever it may beif you eat nothing but broccoli, and Brussels sprouts, and onions, and all these things, take the last year off. It probably won't be that good anyway. So I eat what I like to eat. I'm not venturesome, in that area.

But shhhh, there may be some concessions to health and wellness afoot. Osberg tells Yahoo Finance that Buffett eats salmon once a week. And she reports he now exercises faithfully on his treadmill. The real trick though Osberg says is his attitude. Everybody talks about his attitude and how happy, cheerful he is. Thats the gospel truth. He loves every day. Every single day, he loves. Im not sure I've ever met a person who feels that way. But he does.

On May 2 of this year, three of us; my wife and I, along with Susie Buffett, sat on the empty floor of the CHI Health Center Omaha and watched Buffett and Greg Abel address Berkshire shareholders remotely for the companys annual meeting, (streamed by Yahoo Finance I might add.) As Buffett got up on the platform, he smiled and waved at us, looking spry enough. Little did we know. Buffett then began to speak and answer questions, unscripted for four hours and 28 minutes straight, no breaks, on almost every subject under the sun.

He was impassioned that afternoon, talking about America in the time of COVID-19:

Nothing can stop America when you come down to it, even with the scariest of scenarios. It may have been tested during the Great Depression, and it may be tested now to some degree. In the end the answer is never bet against America. That in my view is true today as it was in 1789 and even was true during the Civil War and depths of the depression, Buffett said.

It was a tour de force, as draining as it was impressive, and it may have been his best, most impactful talk ever.

Not bad for an 89-year-old. And now hes 90.

Here then are birthday wishes from Mario Gabelli, which sound about right:

Warren, holy cow, you're only 90? I want to be there for what the Italians used to say cent'anni, which meant 100. Now, it's centocinquanta, 150 years. That's the birthday party that I'm going to have to give you a birthday wish for. But 90 going to 100 is at least a start. Happy birthday, Warren.

Yes indeed, happy birthday Warren. Long may you run. Whatever youve been doing has worked so far, so please keep doing it.

This article was featured in a Saturday edition of the Morning Brief on August 29, 2020. Get the Morning Brief sent directly to your inbox every Monday to Friday by 6:30 a.m. ET. Subscribe

Andy Serwer is editor-in-chief of Yahoo Finance. Follow him on Twitter: @serwer.

Read the latest financial and business news from Yahoo Finance

Read more

More:
Why Warren Buffett matters more than ever on his 90th birthday - Yahoo Money

Recommendation and review posted by Bethany Smith

The good news is that legions of women scientists have been fighting back against this sexism for years, in many cases with extraordinary success. Being trained to gather data to measure and document problems helped us prove that the issues we faced existed, and the problem-solving skills wed honed in our labs helped us figure out how to address them. For Nancy Hopkins and other women at MIT in the late 1990s, that meant taking out a tape measure and showing that, while senior male professors had labs averaging 3,000 square feet, senior female professors had, on average, just 2,000 square feet in which to workroughly as much as junior male faculty members.

Im happy to say that advances have been made to enhance the participation of women in science, mathematics, technology, engineering, and medicine since I began my career. By the mid-1980s, women in microbiology were banding together to make sure that nominations for leadership positions in professional organizations included womennot just once, but year after year, so that wed have time to make reforms last. During my tenure as director of the National Science Foundation, I worked with the president and Congress to increase the countrys overall budget for research in science, mathematics, and engineering. My team and I also made it a national priority to lift the status of women in academic science and to reform the misogynistic culture of universities. We launched ADVANCE, a program that, from 2001 to 2018, funded contracts to solve problems experienced by women in the sciences on more than 100 campuses.

Despite all of these efforts, major disparities persist. A study last year found that the typical National Institutes of Health research grant to a male principal investigator is $41,000 larger than to a female one. The gap between NIH grants for women and men is even larger at top universities: $68,800 at Yale and $76,500 at Brown.

In 2011, the biologist Jo Handelsman and her team at Yale decided to perform an experiment to see just how bad bias against women in science was. She persuaded 127 scientists in biology, chemistry, and physics departments at six leading research universities across the country to evaluate a job application. Ostensibly, the application came from a recent graduate seeking a position as a laboratory manager, and all of the applications were identical, or almost: half the applications were signed John, and half were signed Jennifer. The disturbing results revealed both men and women scientists judged the male applicant to be more competent than the female applicant with identical qualifications. More faculty members said theyd hire John than Jennifer, and those who were willing to hire her would pay her almost $4,000 less a year. All across the boardno matter their age, sex, scientific field, or tenure statusfaculty members preferred John.

More:
Women Scientists Have the Evidence About Sexism - The Atlantic

Recommendation and review posted by Bethany Smith

Monarch butterflies in one of the reserves of Michoacn (Mexico).Getty Images

Spring is the time when the sex lives of many animals awaken and strategies begin. Male monarchs spray females with aphrodisiac powder and drag them to the ground, writes David Barrie in his work. The most incredible trips (Review, 2020). This powder is the set of chemical pheromones that butterflies use to differentiate themselves. It is a necessary technique to be noticed in the middle of a very dense forest hundreds of meters away, explains Zackary Graham, researcher at the School of Life Sciences of the Arizona State University (United States) and specialist in insects and crayfish.

In the animal world, everyone does everything possible so that it is their sperm that reaches the females egg

Elisa P. Bads, from the University of Groningen (Holland)

Other species are based on sexual dimorphism, that is, on physical differences based on sex, to attract their partners without having to resort to powders aphrodisiacs. Males take advantage of their appearance to attract the attention of females, such as turkeys with their great feathers, newts with their colors and crests, or elk with their antlers. On several occasions, the largest and strongest specimen is the one that seduces the female because it ensures a better offspring.

The Graham Research Team has published a study in the journal Biology Letters about a little-known species that also uses its physical advantages to get a mate: narwhals (Monodon monoceros). Most of the previous hypotheses indicate that the tusk that comes out of their forehead is used to hunt, fight and drive away predators. Although this idea is not ruled out, Graham wanted to go further when he saw that the females did not have one.

Thanks to a collection of data on the behavior of 245 adult narwhals over 35 years, the researchers confirm that these animals use their tusks to demonstrate to other males that they are better and stronger and attract females. If they have a long tusk, it means that their body is proportionally large. And there is the key: Females are more attracted to those that are larger because it indicates more and better quality sperm, explains Graham.

Something similar happens with squid and cuttlefish. The male consorts of some species of squid (Family Loliginidae) are larger than females and use their large size, physical strength, and aggressive skin color to scare off potential competitors while standing guard. Sometimes, they can have half of the body that is directed towards the female with the coloration romantic and the other half with the coloring aggressive, Explains Fernando ngel Fernndez-lvarez, expert in cephalopods and researcher at the Ryan Institute and in the School of Natural Sciences of the National University of Ireland (Galway). However, victory is never assured. An even bigger male can always come along and eject the other, supplant him and begin to copulate with the female.

Some females, depending on the species, have several places where the male can deposit his sperm: near the exit of the oviduct and near the mouth, through the seminal receptacle of the oral membrane. This curious morphology allows them to have eggs from different males. The squids called sneakers (the males more rogues) are the ones who take advantage of this curious feature. These specimens are the same size as the female and give off a similar color to her, so the dominant male, who stands guard, does not perceive them as a threat. However, these small animals approach the female and inoculate their sperm in the oral reproduction zone thanks to a head to head copulation, says Fernndez-lvarez. All this, without the consort noticing.

Squids and cuttlefish are not the only ones to accumulate sexual partners. In the world of birds, polygamy exists more than is believed. Since the 1990s, thanks to genetics, scientists have shown that some socially monogamous birds have copulations outside the nest to ensure good offspring. The objective is to find the best female or the best male to reproduce with quality. This is what Elisa Prez Bads, a researcher at the University of Groningen (Holland) and lead author of a study published in the journal Evolution on the behavior of the tit, a small species with a very striking blue and yellow plumage.

These birds have a very high reproductive rate, of about eight or nine chicks per year, and can take care of up to 16 children in a single nest. The sexual life of this species outside this time is very calm, even non-existent. It is such a strong investment to take care of your children that the rest of the year they are calmer, looking for food and resting to recover all that they have lost. They change their plumage to be beautiful the following spring, says Bads. Both the male and the female, if they are not satisfied with the quality of the eggs or if they see another with a more showy plumage, they can change partners. But in general, it is the female who is going to flutter in search of a male, the most handsome one, the one with the best territory and there she will build her nest, adds the expert.

Frogs and toads use sound to attract females. They go towards the specimen with the most powerful or frequent songs, signs of the good quality of the males genes. A curious thing highlighted by Ignacio De la Riva, an expert researcher on amphibians from the National Museum of Natural Sciences of the Higher Council for Scientific Research, is that, in certain species, there are male satellites that take advantage of the musical qualities of others. Instead of wasting energy singing, these specimens stay quiet near another male that emits sound. When the female approaches, he intercepts her and attempts to mate with her.

The bog lizard, the reptile with the largest land distribution in the world, plays rock, paper or scissors, according to a study published in the journal Biological Science. Patrick Fitze, one of the authors of the work and researcher at the MNCN-CSIC, explains that the species is divided into three colors determined by the alleles (orange, yellow and white) and each one has its territory. For the female, the most interesting thing is to mate with the less frequent color so that her children do not have to compete with the rest of the lizards of the same aspect. If the majority are oranges, it will go for yellow, when yellow multiplies, it will go for white, and then again for orange. And the game begins again, again and again. In this species there are also males sneakers They enter the territory of the other to mate with the females. We have called it rock, paper or scissors because each specimen can choose which strategy to use even if its genetics determine it, explains the researcher.

The strategies of animals to reproduce are numerous and varied. The list is long. Forced copulations can also occur, although uncommon, as does the cat, which uses the spines of its penis to drag and remove the sperm of the previous male, says Elisa P. Bads. In the animal world, everyone does everything possible so that it is their sperm that reaches the females egg, she concludes.

You can follow Matter in Facebook, Twitter, Instagram or subscribe here to our newsletter

More here:
The polygamy of birds, the adultery of squids and other sexual strategies of animals - Pledge Times

Recommendation and review posted by Bethany Smith